Stockwinners Market Radar for July 20, 2023 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service |
EVTC | Hot Stocks19:52 EDT Evertec to acquire Sinqia for BRL27.19 per share - Evertec and Sinqia jointly announced a definitive agreement for Evertec to acquire Sinqia, a leading player in the market of software for financial services in Brazil for consideration with a value of R$27.19 per share, increased by a customary daily "ticking fee" of up to R$1.00 per share depending on the timing of the closing, subject to certain limited exceptions. "Sinqia is a leader in providing software to the financial services industry in Brazil with an impressive history of delivering organic and inorganic growth," said Mac Schuessler, President and Chief Executive Office of Evertec. "This is a highly complementary transaction, and together we plan to bring Evertec payments solutions to Brazil and Sinqia's strategies to our Latin American markets." Pursuant to the terms of the merger agreement, Evertec has agreed to acquire Sinqia's outstanding equity for R$27.19 per share, plus a daily cash ticking fee of up to R$1.00 per share based on the daily SELIC rate published by the Central Bank of Brazil between signing and closing. Based on the closing price of Sinqia shares on July 19, 2023, Sinqia has an equity valuation of R$2,326 million (USD$485 million) and an enterprise value of R$2,835 million (USD$591 million). The transaction represents an approximate 24.0% premium to the unaffected share price at July 19, 2023 and a 22.6% premium to the prior 30-day volume weighted average price. Consideration will be in the form of 90% cash 10% Evertec shares in order to benefit from an expedited process to closing that minimizes execution risk. Evertec has extended and expanded its share repurchase program with the intent of offsetting the impact of newly issued shares as part of the transaction which amount to approximately 1.2 million shares. Evertec intends to finance the acquisition with cash on hand and committed financing of $600 million as the Company looks to maintain a strong balance sheet that provides for added flexibility to continue executing on our diversification and M&A plans. Transaction has been unanimously approved by the boards of directors of both Evertec and Sinqia and is expected to be completed during the fourth quarter of 2023, subject to satisfaction of customary closing conditions and approvals. The transaction is subject to Sinqia stockholder approval of a simple majority (greater than 50%). As of the signing of the merger agreement Evertec has entered into an agreement with shareholders representing approximately 40% of Sinqia's outstanding shares to vote in favor of the transaction. Evertec shareholder approval is not required and is not a condition to closing the proposed transaction. The proposed transaction is expected to be breakeven to slightly accretive to 2024 Adjusted earnings per share and accretive in 2025.
|
NNDM... | Hot Stocks19:07 EDT Stratasys urges shareholders not to be 'misled' by Nano Dimension - Stratasys (SSYS) mailed a letter to shareholders in connection with Stratasys' Annual General Meeting of Shareholders on August 8, 2023. The full text of the letter follows: "The facts are clear and your vote is important. Support the Stratasys Board and VOTE TODAY on the WHITE proxy card "FOR" the re-election of Stratasys' directors. The Stratasys Board urges shareholders NOT to tender into Nano Dimension Ltd.'s (NNDM) coercive partial tender offer, to withdraw any shares previously tendered and to contact their broker and instruct them to file a Notice of Objection. Yoav Stern, Nano's CEO, cannot be trusted and is not trusted by his own shareholders. Don't be misled by Nano and its inconsistent campaign. Why You Should Vote FOR Stratasys' Slate: Stratasys has a highly qualified, independent and diverse Board; Mr. Stern admits that Nano's slate of nominees is not independent; Nano's slate of nominees is unqualified and all but one are officers of Nano; Officers at Nano are not qualified to be Board members of Stratasys, a company that is more than 10x the size of Nano; Voting for Nano's slate of nominees means Nano could take control of Stratasys without paying anything to Stratasys shareholders. Why You Should NOT Tender Your Shares: Nano's partial tender offer means you may have as little as approximately 40% of your shares purchased, assuming full participation in the offer; If Nano's partial tender offer is successful, you could potentially remain a minority shareholder in a Nano-controlled company; Nano's partial tender offer implies that your Stratasys shares are valued at approximately $16 to $19 per share or less, assuming full participation in the offer; Nano has destroyed significant value and displayed disastrous governance."
|
PRCH | Hot Stocks19:03 EDT Porch Group estimates $18M catastrophic weather impact in Q2 - Porch Group announced an estimated $18 million catastrophic weather impact in the second quarter of 2023, due to extreme weather events in June. The second quarter is often the worst and riskiest weather quarter of the year for Porch. The second quarter 2023 was on track until extreme weather events occurred, including wind, thunderstorm and hail events in Texas in mid and late June, which resulted in an estimated $5.0 billion1 in combined industry-wide claims. This will negatively impact operating results2 in the second quarter within the Insurance Segment. Porch preliminarily estimates the extreme weather resulted in a $18 million loss, net of third-party reinsurance. These were uncommon cat weather events compared to historic trends and therefore not included within our full year 2023 guidance. "I'm proud of our team for serving our customers quickly and effectively after these difficult weather events. At Porch, our experienced underwriters continue to use our unique data and analysis of historic trends to evaluate risk when writing insurance policies. Like everyone in the industry, we cannot predict these unfortunate and uncommon weather events, but we will continue to seek to increase prices to ensure we are setup well as we look ahead. Outside of this event, our business is performing well, and we continue to expect to launch the Porch Insurance Reciprocal Exchange later this year, once approved by the Texas Department of Insurance." Matt Ehrlichman, Chief Executive Officer.
|
EVLO BIO | Hot Stocks18:13 EDT Evelo enters into termination and surrender pact with Bio-Rad - According to a regulatory filing, on July 14, 2023, Evelo Biosciences (EVLO) entered into a Sublease Termination and Surrender Agreement with Bio-Rad Laboratories, Inc. (BIO), pursuant to which the parties agreed to terminate that certain Sublease Agreement, by and between the company and Bio-Rad, dated as of December 27, 2017, effective as of September 15, 2023. Under the Sublease, the company leases approximately 40,765 square feet of office and laboratory space located at 620 Memorial Drive in Cambridge, Massachusetts. The Sublease was previously scheduled to terminate, in accordance with its terms, on September 30, 2025, unless sooner terminated or cancelled in accordance with the terms and conditions of the Sublease. As of the Effective Date, the company shall have no further subleasehold or other right, title, or interest in the Premises. In exchange for the early termination of the Sublease pursuant to the Termination Agreement, the company agreed to make a one-time termination payment to Bio-Rad in the amount of $523,556 and Bio-Rad is also entitled to draw on a letter of credit in an amount equal to $850,000 and retain such proceeds. Further, Bio-Rad may be entitled to an additional payment of up to $2,500,000 in connection with the company's completion of a Monetization Event
|
EBS | Hot Stocks18:05 EDT Emergent BioSolutions announces FDA approved CYFENDUS - Emergent BioSolutions announced that the FDA has approved CYFENDUS, or Anthrax Vaccine Adsorbed, Adjuvanted, previously known as AV7909, for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis in persons 18 through 65 years of age when administered in conjunction with recommended antibacterial drugs. The efficacy of CYFENDUS vaccine for post-exposure prophylaxis is based solely on studies in animal models of inhalational anthrax. CYFENDUS vaccine is comprised of Anthrax Vaccine Adsorbed, or AVA, and an additional adjuvant.
|
NEXA | Hot Stocks17:57 EDT Nexa Resources reports drilling strategy for 2023 - Nexa's drilling strategy for 2023 is focused on near-mine expansion brownfield and infill drilling, including the Aripuana, which is in the ramp-up stage. Additional exploratory drilling is also planned for greenfield projects with a favorable perspective. Exploration expenditure and drilling production are running according to budget and schedule. As at the end of the 2Q23, 133,194 meters of cumulative drilling production was carried out, including 41,041 meters of exploratory drilling and 92,153 meters of mining infill drilling. Total exploratory drilling in 2Q23 amounted to 21,607 meters, including 12,029 meters drilled in Peru, 8,699 meters in Brazil, and the remaining 878 meters in Namibia. Exploratory drilling planned for the 3Q23 includes 20,050 meters in Peru with nine rigs, 10,550 meters in Brazil with four rigs, and 4,000 meters in Namibia with two rigs, totaling 34,600 meters.
|
LUMN | Hot Stocks17:53 EDT Lumen appoints Ana White as Chief People Officer - Lumen Technologies has named Ana White Executive Vice President and Chief People Officer. She joins Lumen on September 1. Ana comes to Lumen from her role as Executive Vice President and Chief People Officer at F5, where she was a driving force in their transformation from a hardware-led to a software-led company. She understood that achieving a transformed company was only possible with a transformed culture. Ana spearheaded efforts to cultivate a workplace that is human-first and high-performance, where people are committed to helping each other thrive. Ana brings deep knowledge and experience in driving ground-breaking programs to fuel growth. Her leadership experience includes 18 years at Microsoft, where she led global HR teams. As Microsoft's HR general manager, she partnered with members of the CEO's executive team and oversaw cultural transformation, led several acquisitions, and drove progress in diversity and inclusion.
|
GP | Hot Stocks17:49 EDT GreenPower Motor shares to resume trading on TSX Venture July 21 - GreenPower Motor Company announced that it has been advised by the TSX Venture Exchange that the shares of GreenPower will resume trading on the TSXV effective Friday July 21, 2023 at the opening of trading.
|
STT | Hot Stocks17:36 EDT State Street rises dividend 10% to 69c - State Street announced a quarterly cash dividend of 69c per share of common stock, payable on October 12 to common shareholders of record at the close of business on October 2. The dividend represents a 10% per share increase from the Q2 dividend of 63c per share.
|
FDX | Hot Stocks17:33 EDT FedEx CFO Lenz sells $1.5M in company shares - FedEx CFO Michael Lenz disclosed the sale of 5,745 shares of company stock at $261.88 per share on July 20 for a total transaction amount of $1,504,474.
|
CHWY | Hot Stocks17:27 EDT Chewy CFO Mario Marte to retire, Stacy Bowman named interim CFO - Chewy announced that Mario Marte has decided to retire from the company, effective as of July 28. As part of the transition process, Stacy Bowman, Chief Accounting Officer, has been appointed interim CFO while the company continues its previously announced search for a permanent CFO. Prior to Chewy, Stacy served in a number of senior accounting roles at Brightstar, Ernst & Young and PricewaterhouseCoopers.
|
FUL | Hot Stocks17:17 EDT H.B. Fuller announces additional restructuring actions - H.B. Fuller announced that it was implementing an additional strategic restructuring to expedite the integration of recently acquired businesses and drive overall operational improvements. The restructuring actions, prompted by the recent acquisition of Beardow Adams, will accelerate profitable growth in many of our core end markets, while streamlining operations and enhancing customer service. As part of our standard acquisition integration process, and in conjunction with ongoing efforts to review our manufacturing footprint, several opportunities were identified to further optimize our global manufacturing and supply chain operations. This will result in the closure of three manufacturing facilities and the redistribution of production across the network to improve overall efficiency. "We are executing our strategic plan to improve our business model, our portfolio, and our customer experience, augmented by our position as the acquirer of choice in the adhesives industry," said Celeste Mastin, president and CEO. "Acquisitions enable us to expand our market share and network, bring in new talent and technology, and provide a new framework from which to optimize production efficiency." These actions will be initiated in the third quarter of fiscal year 2023 and are expected to be completed in fiscal year 2026. Restructuring costs of approximately $20M (pre-tax) will be spread across the next several fiscal quarters as these measures are implemented. Once completed, this restructuring is expected to result in on-going annualized cost savings of approximately $20M (pre-tax). The majority of the restructuring charges and cost savings are expected to be recognized in fiscal year 2024.
|
MDRX | Hot Stocks17:16 EDT Veradigm announces two healthcare provider agreements in Q2 - Veradigm announced the signing of two multi-year healthcare provider agreements during the Q2. One of Veradigm's largest Veradigm EHR clients, State of Franklin Healthcare Associates, or SOFHA, a physician-owned and led primary care and multi-specialty healthcare system in upper East Tennessee and Southwest Virginia, expanded its agreement with Veradigm to include Veradigm Revenue Cycle Services. Also, during the quarter, Total Orthopedics and Sports Medicine contracted for Veradigm Revenue Cycle Services, Veradigm Payerpath, Veradigm Guided Scheduling and Veradigm FollowMyHealth to enhance their patient experience and billing process.
|
CYBN | Hot Stocks17:07 EDT Cybin says study validates Kernel's flow1 neuroimaging technology - Cybin commends Kernel, a leader in non-invasive neuroimaging, on their publication titled "Measuring acute effects of subanesthetic ketamine on cerebrovascular hemodynamics in humans using TD-fNIRS" in the journal Scientific Reports from the Nature Portfolio of Journals. The publication highlights the results of the Cybin-sponsored Flow1 feasibility study demonstrating the capabilities of the Flow1 system to capture and analyze brain changes resulting from the administration of a psychoactive substance. The feasibility study is the largest functional near-infrared spectroscopy study to measure the acute effect of a psychedelic and is the first ever fNIRS neuroimaging study evaluating ketamine in humans... "It was great to partner with Cybin on this work because of their commitment to pushing the boundaries to solve challenging problems. This collaboration paves the way for large-scale clinical studies using our Flow technology, which enables the quantification of psychedelics' impact on the brain." "The feasibility study is truly groundbreaking as it supports Kernel's ability to measure functional brain activity in real time, using a wearable, convenient device. The study results also suggest that a combination of metrics may be predictive of subjective mystical experiences during psychedelic treatment," said Doug Drysdale, Chief Executive Officer of Cybin. "We are excited about the potential for this technology in expanding our understanding of the mechanisms and effects of psychedelic-based therapeutics on the brain and applications to research and clinical trials, which is essential to Cybin's goal of developing differentiated therapeutics for people with mental health conditions.
|
CDTX JNJ | Hot Stocks17:03 EDT Cidara Therapeutics provides update on status of CD388 program - Cidara Therapeutics (CDTX) provided an update on the status of its ongoing CD388 program for prevention of influenza A and B, which is the subject of an exclusive worldwide license and collaboration agreement with Janssen Pharmaceuticals, one of the Janssen Pharmaceutical Companies of Johnson & Johnson (JNJ). As part of a recent prioritization of its R&D business, Janssen has announced its intention to discontinue internal development of the majority of its infectious disease pipeline, including JNJ-0953. However, at this time, Janssen has not informed Cidara of any intention to terminate the agreement between the two parties. Cidara continues to work in collaboration with Janssen to complete the Phase 1 and Phase 2a clinical trials and will be reimbursed for all ongoing development activities by Janssen as per the Janssen Collaboration Agreement. Under the Janssen Collaboration Agreement, within 90 days after Cidara delivers the complete CD388 Phase 2a data package to Janssen, Janssen is required to notify Cidara whether it will proceed with clinical development. If Janssen delivers an Election to Proceed, it is obligated at its sole expense to diligently continue development and commercialization either itself or through a third party to whom it sublicenses or assigns the rights. If Janssen sublicenses or assigns the rights to a third party, then all terms under the current Janssen Collaboration Agreement will survive without modification. Should Janssen not provide an Election to Proceed within the Election Period, Cidara would have the right to terminate the agreement and retain the CD388 program, including all data and materials funded by Janssen's investment in the program.
|
ISRG | Hot Stocks17:03 EDT Intuitive Surgical raises FY23 procedure growth view to 20%-22% from 18%-21% - Sees FY23 gross profit margin 68%-69%. Says actual gross margin will vary quarter to quarter. Sees FY23 operating expense growth 12%-15%. Sees FY23 capital expenditures $800M-$1B. Sees FY23 tax rate 22%-24%.
|
DWAC | Hot Stocks16:58 EDT SEC charges Digital World SPAC for material misrepresentations to investors - The Securities and Exchange Commission announced settled fraud charges against Digital World Acquisition Corporation, a special purpose acquisition company, for making material misrepresentations in forms filed with the SEC as part of DWAC's initial public offering and proposed merger with Trump Media & Technology Group Corp. The Commission finds that DWAC misled investors and the SEC by failing to disclose that it had formulated a plan to acquire and was pursuing the acquisition of TMTG prior to DWAC's IPO. The purpose of a SPAC is to identify and acquire an operating business. As such, steps taken by a SPAC in furtherance of a particular acquisition are important to investors. According to the SEC's order, DWAC filed an amended Form S-1 in support of its IPO in early September 2021 that stated that neither DWAC nor its officers and directors had had any discussions with any potential target companies prior to the IPO. But, as found in the SEC's order, dating back to February 2021, an individual who would later become DWAC's CEO and Board Chairman, and others involved with DWAC, had extensive SPAC merger discussions with TMTG. The SEC's order further finds that, while DWAC's CEO and Chairman initially pursued these discussions with TMTG on behalf of another SPAC, he created a plan in the spring and summer of 2021 to potentially use DWAC to pursue a merger with TMTG and used this plan to solicit certain pre-IPO investors. The order also finds that DWAC failed to disclose that the CEO had a potential conflict of interest based on an agreement he had signed with TMTG. As a result, DWAC's amended Form S-1 was materially false and misleading. The SEC's order further states that, in a later Form S-4 filed with the Commission following the announcement of the proposed merger with TMTG, DWAC mischaracterized and omitted information about the history of its interactions with TMTG. The SEC's order finds that DWAC violated the antifraud provisions of the federal securities laws. DWAC agreed to a cease-and-desist order and to pay an $18 million penalty in the event it closes a merger transaction. It also agreed to undertake that, should DWAC file an amended Form S-4, any such Form S-4 will be materially complete and accurate and consistent with the findings in the SEC's order.
|
DRI | Hot Stocks16:52 EDT Darden chairman Lee sells 33,000 common shares - In a regulatory filing, Darden Restaurants chairman of the board Eugene Lee, Jr. disclosed the sale of 33,000 common shares of the company on July 19 at a price of $170.09 per share.
|
GNLX | Hot Stocks16:52 EDT Genelux promotes Joseph Cappello to chief technical officer - Genelux announced Joseph Cappello, who previously served as the company's VP of pharmaceutical development, has been promoted to chief technical officer. .
|
IGT | Hot Stocks16:34 EDT International Game upgrades upgraded Poland's national lottery operator - International Game Technology announced that it has upgraded Poland's national lottery operator Totalizator Sportowy's iLottery platform and deployed all of its components to the cloud. This go-live marks the first time that IGT has launched a customer's comprehensive iLottery platform to the cloud and Totalizator Sportowy is the first European lottery to have its end-to-end iLottery system on the cloud.
|
ARVL | Hot Stocks16:33 EDT Nasdaq grants Arrival required extension to file annual report on Form 20-F - Arrival announced that the Nasdaq Stock Marke has determined to grant Arrival an exception to Listing Rule 5250(c)(1) , giving Arrival an extension of the deadline to file its Annual Report on Form 20-F for the fiscal year ended December 31 .As Arrival announced in its press release dated May 5 on May 2 , Arrival received a deficiency letter from Nasdaq notifying Arrival that due to its failure to file the 2022 20-F within the prescribed period of time, Arrival no longer complied with the Rule, which requires timely filing of all required periodic financial reports with the U.S. Securities and Exchange Commission. Nasdaq informed Arrival that it had sixty (60) calendar days to submit a plan of compliance to Nasdaq detailing how the Company planned to file the 2022 20-F and regain compliance with Nasdaq's continued listing requirements.
|
KTB | Hot Stocks16:33 EDT Kontoor Brands appoints Kidd as EVP, Chief Human Resources Officer - Kontoor Brands announced the appointment of Pete Kidd as Executive Vice President, EVP, and Chief Human Resources Officer, effective July 20, 2023. Kidd will be responsible for the company's global human resources strategy and operations including total rewards, talent acquisition and retention, talent and organizational development, and HR information systems. Prior to his appointment to EVP and Chief Human Resources Officer, Kidd was Kontoor Brands Senior Vice President, Global Total Rewards, since joining the company in 2022.
|
TRTL | Hot Stocks16:33 EDT TortoiseEcofin Acquisition Corp. III announces LOI for business combination - TortoiseEcofin Acquisition Corp. III announced that it has executed a new non-binding letter of intent for a proposed business combination with an industrial renewable power solutions company that would result in a public listing of the Target upon completion of the proposed Business Combination. The Company previously signed an initial LOI with the Target on April 26, 2023 and anticipates announcing additional details regarding the execution of a definitive agreement for the Business Combination, which is expected in the third quarter of 2023. "Our commitment to the energy transition is unwavering and is supported by our deep sector expertise and long track record of value creation over decades of investing in the energy and power infrastructure sector," commented Vince Cubbage, Chief Executive Officer of TortoiseEcofin Acquisition Corp. III. "In assessing potential business combination targets, we have focused on companies that are developing specific solutions to current, real-world problems. We are excited by the potential transaction identified with this pioneering industrial renewable power solutions company. We expect that this company will play a critical role in facilitating the energy transition for the industrial market." As a result of the signed letter of intent, pursuant to the provisions of the Company's Amended and Restated Memorandum and Articles of Association, the Company has until October 22, 2023 to consummate its business combination.
|
PLYM | Hot Stocks16:33 EDT Plymouth Industrial REIT chief investment officer transitions from role - Plymouth Industrial REIT announced that Pendleton White, its co-founder, has transitioned from his executive role as president and chief investment officer. White will remain on the company's board of directors and advise Plymouth on its overall corporate strategy and acquisition activities.
|
BOWL | Hot Stocks16:32 EDT Bowlero announces acquisitions in Arizona - Bowlero announced they have entered into a definitive agreement to acquire Mavrix and Octane Raceway in Scottsdale, Arizona. This transaction is expected to close at the end of August 2023, and will be funded through an all cash transaction. The acquisition of Mavrix and Octane Raceway will mark the company's 19th and 20th locations in Arizona. "The acquisitions of Mavrix and Octane Raceway align seamlessly with our commitment to providing premium and immersive experiences to our guests," stated Thomas Shannon, Founder, President and CEO of Bowlero Corp. "Our decision to incorporate these dynamic venues in our growing portfolio exemplifies the company's dedication to furthering our position as the leader in the entertainment space."
|
SYF | Hot Stocks16:31 EDT Synchrony increases dividend 9% to 25c - Synchrony Financial announced that its Board of Directors declared a quarterly cash dividend of 25c per share of common stock, payable on August 10 to holders of record at the close of business on July 31. The Board of Directors also declared a quarterly cash dividend on the outstanding shares of its 5.625% Fixed Rate Non-Cumulative Perpetual Preferred Stock, Series A. Each outstanding share of the Series A Preferred Stock is represented by depositary shares, each representing a 1/40th interest in a share of Series A Preferred Stock. The dividend of approximately $14.06 per share is payable on August 14 to holders of record at the close of business on July 31.
|
BIO | Hot Stocks16:31 EDT Bio-Rad announces up to $500M share repurchase program - Bio-Rad Laboratories announced that its board of directors approved a new share repurchase program that grants the company authority to repurchase up to $500M of outstanding shares of its common stock. "The new share buyback authorization is consistent with our disciplined approach and demonstrates our continued commitment to using this tool as part of our capital allocation strategy," said Norman Schwartz, Bio-Rad's Chief Executive Officer.
|
MRIN PINS | Hot Stocks16:31 EDT Marin Software announces new Pinterest integrationPinterest - Marin Software (MRIN) announced the ability to manage Pinterest (PINS) ad campaigns through its flagship MarinOne platform. The new integration with Pinterest's Marketing API gives advertisers better insights and helps them improve the performance of their Pinterest campaigns through machine learning and automation. "We look forward to providing our customers an avenue to integrate our powerful reporting, advanced bidding, and campaign management tools to achieve the best performance on the Pinterest platform." said Chris Lien, Marin's Chairman and CEO.
|
SLM | Hot Stocks16:30 EDT SLM names Munish Pahwa chief risk officer - Sallie Mae, formally SLM Corporation, has named Munish Pahwa Executive Vice President and Chief Risk Officer. Pahwa will be accountable for the company's integrated risk and compliance function and maintaining strong relationships with regulators. He succeeds Kerri Palmer, who was named Chief Operational Officer and President of Sallie Mae Bank earlier this year. Pahwa has served as Chief Credit Risk Officer for Sallie Mae since 2021. Prior to joining Sallie Mae, he spent nearly 16 years at Bank of America in various risk roles. Pahwa also held roles in Risk, Collections, Operations, and Decision Sciences at MBNA, PNC Bank, and Bank of New York Mellon.
|
SWVL | Hot Stocks16:30 EDT Swvl gets approval to switch listing to the Nasdaq Capital Market - Swvl Holdings confirms that Nasdaq has accepted the Company's plan to regain compliance in connection with the delayed filing of its Annual Report on Form 20-F for the year ended December 31. Nasdaq has granted the Company an exception, enabling it to regain compliance with the listing rules by filing its 2022 20-F by October 30, 2023. In addition, Swvl announced today that it received approval from the Nasdaq Stock Market of the Company's request to transfer its listing to the Nasdaq Capital Market from the Nasdaq Global Market. Trading on the Nasdaq Capital Market commenced effective with the open of business on July 19 under Swvl's current ticker symbols, "SWVL" and "SWVLW." The Nasdaq Capital Market operates in substantially the same manner as The Nasdaq Global Market, including a requirement that companies listed on The Nasdaq Capital Market maintain certain financial requirements and corporate governance standards in order to maintain continued listing.
|
CDXS | Hot Stocks16:28 EDT Codexis sees FY23 product revenue $30M-$35M - The company said, "Codexis is reiterating its 2023 product revenue and gross margin guidance as outlined in the Company's first quarter earnings release issued on May 4, 2023. Specifically, product revenues are expected to be in the range of $30 million to $35 million and gross margin on product revenue is expected to be in the range of 55% to 65%; both metrics exclude enzyme sales related to PAXLOVID. R&D revenues are now expected to be in the range of $21 million to $24 million, compared to previous guidance of $28 million to $33 million. The change is the result of the workforce reduction and reduced R&D expenses subject to reimbursement related to the discontinuation of the Company's Biotherapeutics programs. As of June 30, 2023, the Company had an estimated $92.1 million in cash and cash equivalents. Codexis expects the portfolio prioritization, operational streamlining and reduction in workforce to significantly reduce the Company's annual cash burn rate for its planned operations, extending cash runway into mid-2026 and funding critical upcoming milestones for its priority programs."
|
CDXS | Hot Stocks16:24 EDT Codexis to discontinue developments in Biotherapeutics, reduce headcount by 25% - Codexis announced that the company intends to prioritize the advancement and commercialization of its Enzyme-Catalyzed Oligonucleotide, or ECO, Synthesis platform and its highly complementary Pharmaceutical Manufacturing business. As part of this strategic focus, the company is streamlining operations, including discontinuing investment in certain development programs, primarily in Biotherapeutics, consolidating operations to its headquarters and reducing headcount by approximately 25%. Codexis had $92.1 million in cash and cash equivalents as of June 30, 2023, and with these changes expects that this balance will be sufficient to fund its planned operations to mid-2026, providing the Company the opportunity to deliver on critical milestones related to its ECO Synthesis platform. Codexis is planning to discontinue its 50/50 development support of CDX-7108 and is in active negotiations with its partner, Nestle Health Science S.A., to advance the program. CDX-7108 is being developed for the treatment of exocrine pancreatic insufficiency. The company is actively exploring options to drive value by potentially monetizing other assets within its Biotherapeutics portfolio. To align with the company's portfolio updates, Codexis is reducing its headcount by approximately 25%. The company expects the majority of these changes will be complete by September 30 and estimates it will begin to realize associated savings in the fourth quarter of this year. Codexis will consolidate operations from its San Carlos, California facility to its headquarters in Redwood City, California. The move is expected to occur during the second half of 2023. As a result of these changes, the company expects to reduce annual expenses by approximately $15M in R&D and $5M in Selling, general and administrative, as well as avoid a significant ramp-up in expenses related to Biotherapeutics.
|
PPG | Hot Stocks16:23 EDT PPG: Higher Q3 tax rate to have y/y impacted on adjusted EPS of 7c-9c - In prepared commentary ahead of its earnings conference call, PPG said it expects Q3 corporate expenses of about $90M, with net interest expense of $35M-$37M and an effective tax rate of 23%-24%. This higher effective tax rate is expected to have an unfavorable year-over-year impact on adjusted Q3 EPS of approximately 7c-9c.
|
SHPW | Hot Stocks16:23 EDT Shapeways to transfer listing to Nasdaq - Shapeways Holdings announced its decision to transfer its listing to The Nasdaq Global Market from the New York Stock Exchange. Shapeways expects its common stock and warrants to list on Nasdaq at the open of business on August 1, 2023, under the symbols "SHPW" and "SHPWW". "We are excited to move to Nasdaq and join many of the world's leading technology companies as Shapeways continues to push the boundaries of digital manufacturing and software solutions," said Greg Kress, CEO of Shapeways. "This move should allow us to benefit from Nasdaq's cost-effective offering, while also providing us with a platform to expand our market presence, reach a broader investor base, and accelerate our growth trajectory. This transition reflects our commitment to innovation, customer success, and shareholder value creation."
|
MBSC | Hot Stocks16:21 EDT M3-Brigade Acquisition III approves extension period for business combination - M3-Brigade Acquisition III announced that, upon the request of the Company's sponsor, M3-Brigade Sponsor III, its board of directors has approved an extension of the period of time the Company has to consummate its initial business combination by three months, from the current deadline of July 26 until October 26, pursuant to the Company's amended and restated certificate of incorporation. The Charter permits a total of four three-month extensions, of which this is the fourth. In connection with the Extension, the Sponsor, or its affiliates or designees, will deposit an additional $1,696,500 into the Company's trust account, in part from the Company's working capital, for the benefit of the Company's public stockholders. The Company's stockholders are not entitled to vote on or redeem their shares in connection with the Extension.
|
RITM GS | Hot Stocks16:20 EDT Rithm Capital acquires $1.4B of Marcus loans from Goldman Sachs - Rithm Capital Corp. (RITM) announced the purchase of $1.4B of prime unsecured consumer loans from The Goldman Sachs Group (GS). The portfolio was originated and serviced by Goldman Sachs through the Marcus program. The pool represents a portion of the broader Marcus portfolio that was previously owned and held on balance sheet by Goldman Sachs. The pool is comprised of 100% fixed-rate closed-end installment loans in which ~95% of the pool was originated between 2021 Q4 and 2022 Q4 from the post-COVID demand boost. Acquiring these consumer loans allows for an opportunity for Rithm Capital to add discounted, short duration and high yielding prime credit consumer assets. "This purchase is extremely attractive to us building off our past and current expertise in consumer finance," said Michael Nierenberg, Chairman, Chief Executive Officer and President of Rithm Capital. "Consistent with our investment approach, we continue to look for opportunities to grow shareholder value and believe this transaction will be an excellent addition."
|
EQT | Hot Stocks16:19 EDT EQT Corporation appoints Jeremy Knop as CFO - EQT announced Jeremy Knop has been named CFO following completion of the Company's previously announced succession process. Knop, who previously served as the Company's Executive Vice President of Corporate Development, will assume the CFO role effective July 24. Knop has extensive experience in strategic decision making, investment management, capital allocation, M&A and transaction execution. In his previous role at EQT, Knop was responsible for leading EQT's M&A strategy since joining the Company in January 2021. Prior to joining EQT, Knop was a Principal at The Blackstone Group focused on debt, mezzanine and private equity investing across the energy industry. While at Blackstone, his responsibilities included investment due diligence, execution, and portfolio management, including serving on the board of directors of various portfolio companies. Prior to joining Blackstone in 2012, Knop was an investment banker in the global natural resources group at Barclays. Knop received a BBA in Finance from Texas A&M University. Knop and outgoing CFO, David Khani, have worked closely together during their shared tenure at EQT on matters such as financial policy, capital allocation and hedging, which will support strategic continuity and a smooth transition.
|
CVS UAL | Hot Stocks16:19 EDT CVS Health appoints Scott Kirby to Board of Directors - CVS Health (CVS) has appointed J. Scott Kirby, CEO of United Airlines Holdings (UAL), to serve on the Board of Directors of CVS Health, effective October 1.
|
SGMT | Hot Stocks16:16 EDT Sagimet Biosciences announces COO Rimac assumes position of CFO - Sagimet Biosciences announced a series of leadership changes and appointments, designed to ensure a seamless transition into the next stage of growth for the company. Elizabeth Rozek was appointed earlier this year as General Counsel & Chief Compliance Officer, and Anthony M. Rimac, who currently serves as Chief Operating Officer, will assume the position of Chief Financial Officer as of August 1. Dennis Hom, our current CFO, will continue to serve in an advisory capacity for several months. In addition, Gordon Ringold, Ph.D., and James F. Young, Ph.D., have stepped down from the board of directors as of July 13.
|
TPIC | Hot Stocks16:13 EDT TPI Composites hires Neil Jones as Chief Quality Officer, effective August 1 - TPI Composites, announced that it has hired Neil Jones as its Chief Quality Officer, effective August 1. In this newly-created position, Neil will oversee all quality processes, systems and controls relating to TPI's wind business and will report directly to TPI's President and Chief Executive Officer, Bill Siwek. Bill Siwek, TPI's President and CEO commented, "We are thrilled to have Neil join TPI. I am confident that Neil will bring fresh insights, innovative ideas, and an unwavering dedication to quality excellence and help enhance the quality culture at TPI."
|
ADCT | Hot Stocks16:12 EDT ADC Therapeutics to discontinue LOTIS-9 clinical trial - ADC Therapeutics announced that it plans to discontinue the Phase 2 LOTIS-9 clinical trial evaluating Zynlonta and rituximab in unfit or frail patients with previously untreated diffuse large B-cell lymphoma, or DLBCL. Given the challenges of defining the addressable segment of the difficult-to-treat unfit or frail DLBCL patient population, including many patients with significant active underlying co-morbidities, the benefit-risk profile does not support continuation of the LOTIS-9 trial. Following a meeting yesterday, the FDA placed a partial clinical hold on the trial for new patient enrollment but will allow patients already on therapy who are deriving clinical benefit to remain on therapy after being reconsented. Following treatment of any reconsenting patients, the company will conduct the necessary steps to conclude the trial and does not plan to continue studying this regimen in the unfit or frail previously untreated DLBCL patient population.
|
RKLB | Hot Stocks16:11 EDT Rocket Lab announces next Electron launch window - Rocket Lab USA announced it has scheduled its next Electron launch during a window that opens 28 July 2023 NZST/UTC. The 'We Love the Nightlife' mission is scheduled to launch from Rocket Lab Launch Complex 1 on New Zealand's Mahia Peninsula for American space tech company Capella Space (Capella), a leading provider of commercial Synthetic Aperture Radar (SAR) imagery. 'We Love the Nightlife' will be Rocket Lab's third launch for Capella following the successful "Stronger Together" mission launched in March 2023 from Rocket Lab Launch Complex 2 in Virginia, USA, and the "I Can't Believe It's Not Optical" mission in August 2020 from Launch Complex 1, which deployed the first satellite in Capella's SAR constellation. Rocket Lab founder and CEO, Peter Beck, said: "Electron was the trusted launch vehicle for Capella's first publicly available satellite when we launched their mission in 2020, so it's an honor once again to be entrusted with launching the first of their next generation Acadia satellites. Reaching 40 Electron launches is a wonderful milestone for our team members who have built the most reliable small launch vehicle in history and we're delighted to share such a significant launch with our long-standing mission partner Capella."
|
COF | Hot Stocks16:09 EDT Capital One reports Q2 net charge-offs $2.2B - Provision for credit losses decreased $305M to $2.5B.
|
BNRG | Hot Stocks16:09 EDT Brenmiller Energy receives Nasdaq minimum bid price notification - Brenmiller Energy announced that it has received a written notice from the Nasdaq Stock Market LLC indicating that the Company is not in compliance with the minimum bid price requirement for continued listing set forth in Nasdaq Listing Rule 5550(a)(2), which requires listed securities to maintain a minimum bid price of $1.00 per share. Under Nasdaq Listing Rule 5810(c)(3)(A), the Company has been granted a grace period of 180 calendar days to regain compliance with the minimum bid price requirement. The Notice does not immediately affect the Company's Nasdaq listing or the trading of its ordinary shares. During the grace period, as may be extended, the Company's ordinary shares will continue to trade on Nasdaq under the symbol "BNRG". According to the Notice, the Company has until January 10, 2024, to regain compliance with the minimum bid price requirement. The Company can regain compliance if, at any time during this 180-day period, the closing bid price of its ordinary shares is at least $1.00 for a minimum of ten consecutive business days, in which case the Company will be provided with written confirmation of compliance and this matter will be closed. In the event that the Company does not regain compliance after the initial 180-day period, the Company may then be eligible for an additional 180-day compliance period if it meets the continued listing requirement for market value of publicly held shares and all other initial listing standards for the Nasdaq Capital Market, with the exception of the minimum bid price requirement. In this case, the Company will need to provide written notice of its intention to cure the deficiency during the second compliance period.
|
VLO | Hot Stocks16:08 EDT Valero names Gary Simmons COO - Valero Energy Corporaion announced that Gary K. Simmons, Valero's Executive Vice President and Chief Commercial Officer, has been promoted and elected by the Board of Directors as Executive Vice President and Chief Operating Officer of Valero, effective July 20, 2023. Gary has led Valero's commercial organization since 2014 and has served as Executive Vice President and Chief Commercial Officer since January 2020. In his new role as Executive Vice President and Chief Operating Officer, Gary will also have oversight responsibility for all refining operations. "Gary has done a great job during his long tenure with Valero," said Lane Riggs, Valero's Chief Executive Officer, President and member of the Board. "I look forward to continuing to work with him and our team in advancing our strategy of pursuing excellence in operations, maintaining discipline on returns and honoring our commitments to stockholders."
|
SCHL | Hot Stocks16:08 EDT Scholastic approves additional $100M for repurchase program - The Company's Boards of Directors has authorized an additional $100M for repurchases of its common stock under the Company's stock repurchase program. Under this program, which will continue to be funded with available cash, the Company expects to continue purchasing shares, from time to time as conditions allow, on the open market or in negotiated private transactions for the foreseeable future.
|
COF | Hot Stocks16:06 EDT Capital One reports Q2 net interest margin of 6.48%, down 12 bps vs. Q1
|
CDNS RMBS | Hot Stocks16:05 EDT Cadence to acquire Rambus PHY IP business - Cadence Design (CDNS) and Rambus (RMBS) announced that they have entered into a definitive agreement for Cadence to acquire the Rambus SerDes and memory interface PHY IP business. Rambus will retain its digital IP business, including memory and interface controllers and security IP. The expected technology asset purchase also brings Cadence proven and experienced PHY engineering teams in the United States, India and Canada, further expanding Cadence's domain-rich talent base. The transaction is expected to be immaterial to revenue and earnings this year for each company. It is expected to close in the third calendar quarter of 2023, subject to certain closing conditions.
|
CCOEY... | Hot Stocks15:46 EDT Capcom says 'Resident Evil 4' remake has sold over 5M units worldwide - Capcom (CCOEY) announced that the multiplatform title "Resident Evil 4," a remake of the 2005 game of the same name, has sold over 5M units worldwide. The game launched March 24, 2023 for PlayStation 5 (SONY), PS4, Xbox Series X/S (MSFT), and PC. Reference Link
|
AMZN | Hot Stocks15:28 EDT Amazon fined $25M penalty for alleged violation of COPPA relating to Alexa - The Justice Department, together with the Federal Trade Commission, on Wednesday announced that Amazon.com Inc. and its wholly-owned subsidiary Amazon.com Services LLC, have agreed to a permanent injunction and a $25M civil penalty as part of a settlement to resolve alleged violations of the Children's Online Privacy Protection Act , or COPPA, the Children's Online Privacy Protection Rule and the Federal Trade Commission Act relating to Amazon's voice assistant service Alexa. In a complaint filed in the U.S. District Court for the Western District of Washington, the government alleges that, since at least May 2018, Amazon violated the FTC Act, COPPA and the COPPA Rule with respect to Alexa and Alexa's child-directed offerings. The complaint alleges that Amazon retained children's voice recordings indefinitely by default, in violation of COPPA's requirement that these recordings be retained only as long as reasonably necessary to fulfill the purposes for which they were collected. The order imposes injunctive relief that requires Amazon to identify and delete inactive child profiles unless a parent requests that they be retained. Amazon also will notify parents whose children have accounts of this change to its policies. The order further prohibits Amazon from making misrepresentations about Amazon's retention, access to or deletion of geolocation information or voice information, including children's voice information, and mandates deletion of geolocation information, voice information, and children's personal information upon the request of the user or parent, respectively. Reference Link
|
BK... | Hot Stocks15:05 EDT Federal Reserve announces FedNow Service now live - The Federal Reserve on Thursday announced that its new system for instant payments, the FedNow Service, is now live. Banks and credit unions of all sizes can sign up and use this tool to instantly transfer money for their customers, any time of the day, on any day of the year. To start, 35 early-adopting banks and credit unions, as well as the U.S. Department of the Treasury's Bureau of the Fiscal Service, are ready with instant payments capabilities via the FedNow Service. In addition, 16 service providers are ready to support payment processing for banks and credit unions. When fully available, instant payments will provide substantial benefits for consumers and businesses, such as when rapid access to funds is useful, or when just-in-time payments help manage cash flows in bank accounts. For example, individuals can instantly receive their paychecks and use them the same day, and small businesses can more efficiently manage cash flows without processing delays. Over the coming years, customers of banks and credit unions that sign up for the service should be able to use their financial institution's mobile app, website, and other interfaces to send instant payments quickly and securely. Among the early adopter financial institutions are BNY Mellon (BK), JPMorgan Chase (JPM), U.S. Bank (USB), and Wells Fargo (WFC). Service providers supporting payment processing for financial institutions include ACI Worldwide (ACIW), BNY Mellon, FIS (FIS), Fiserv Solutions (FISV), and Jack Henry (JKHY). Other publicly traded companies in the space include Visa (V) and MasterCard (MA). Reference Link
|
SIRI | Hot Stocks14:48 EDT Sirius XM up 38% to $7.55 as late day advance continues
|
SIRI | Hot Stocks14:36 EDT Sirius XM halts again with shares up 30% to $7.15
|
SLG | Hot Stocks14:32 EDT SL Green Realty CEO 'very comfortable' with where dividend is today - SL Green Realty CEO Marc Holliday responded to an analyst question about the company's dividend by stating, according to a transcript of the company's Q2 earnings call: "[We] think when people invest in SL Green buyer stock, it's a blended play. People want current return, and they want evidence of our ability to be able to generate cash flow either through ordinary operations or gain on assets and be able to reward shareholders throughout the year with the dividend in addition to doing our redevelopments and developments and creating growth and driving share value. And in most years, that's reflected in some years, like we have today, where the market sentiment is very negative, we just work our way through that. But I think what I wanted to state is that we believe that a dividend is an important component of the overall investment thesis for anybody to invest in the stock. We all own the stock at the managerial level for most of us. It is the largest, if not almost the exclusive source of our net worth is the stock that we own. And we want to create value, and we want to create cash flow and see distributions in the form of dividends. So we are very comfortable with where the dividend is today, given the earnings that we're generating and the gains that we're generating on some of these very important sales, we'll do next year's business plan next year. we'll have a sit down in November, December, and we'll roll that entire plan out with our objectives and our earnings levels, et cetera. But suffice it to say, which is what I said earlier is we take all of those points very seriously. And our goal is as best as possible to maintain the levels as much as we can."
|
SIRI | Hot Stocks14:27 EDT Sirius XM trading resumes
|
SIRI | Hot Stocks14:23 EDT Sirius XM halted for volatility after jumping 21% to $6.67
|
SIRI | Hot Stocks14:22 EDT Sirius XM trading halted, volatility trading pause
|
HZNP | Hot Stocks14:15 EDT Horizon Therapeutics' Tepezza labeling adds warning about hearing loss - An FDA letter to Horizon Therapeutics dated July 17 indicated that the company's supplemental biologics license application, or sBLA, was approved and provides for additions to the WARNINGS AND PRECAUTIONS, ADVERSE REACTIONS, and PATIENT COUNSELING INFORMATION sections of the Prescribing Information. The Prescribing Information now states that Tepezza "may cause severe hearing impairment including hearing loss, which in some cases may be permanent. Assess patients' hearing before, during, and after treatment with Tepezza and consider the benefit-risk of treatment with patients." Reference Link
|
AMC | Hot Stocks13:39 EDT AMC Theatres abandons Sightline at AMC pricing initiative - AMC Theatres will soon complete the Sightline at AMC pilot test program at select locations in three U.S. markets. The company said, "The results of this pilot program clarified consumer reaction to seat-based pricing within a movie theatre. Among all theatres participating in the Sightline at AMC pilot, AMC saw the following results: More than 3 out of 4 AMC Stubs members who previously purchased tickets within the Preferred Sightline sections of the theatre continued to select those seats, even with the slight upcharge applied. More than 1 out of 10 AMC Stubs members selected a seat outside the Preferred Sightline section, where there was no additional charge. AMC saw little or no incremental lift in front-row attendance, even with a price reduction applied to those seats. To ensure its ticket prices stay competitive, Sightline at AMC will not continue at the current pilot locations once the test ends in the coming weeks, and the program will not roll out nationwide. But AMC is applying its learnings as it pivots to its next innovation - enhanced spacious front row seating with extensive seat recline. Beginning in late 2023, AMC will begin testing its newest seating concept. Large, comfortable lounge style seating areas will allow guests to lay all the way back and relax. The angle of the seats will also make it more enjoyable to watch movies from these front row seats closest to the screen."
|
SAP | Hot Stocks12:24 EDT SAP falls 4% to $136.73 after reporting Q2 results
|
SAP | Hot Stocks12:17 EDT SAP trading resumes
|
GILD | Hot Stocks12:01 EDT Gilead announces $8M in funding through Gilead Relink program - Gilead Sciences is providing a total of $8M in funding through a new grant program in the United States called Gilead Relink, which is focused on bringing diagnosed but untreated people living with hepatitis C virus or hepatitis B virus back into care. The CDA Foundation based in Lafayette, Colorado, will act as the lead organization for the program and be responsible for implementing and overseeing Gilead Relink, including distributing funds to grantees identified by CDAF that meet certain criteria, integral strategic planning and technical assistance. The Gilead Relink grant program aims to identify and bridge the gaps that remain in linking people living with HCV and HBV back to necessary care and treatment by prioritizing three programmatic areas - utilizing evidence-based solutions, leveraging successful intervention and data collection models, and emphasizing knowledge sharing and convening.
|
SLG | Hot Stocks12:00 EDT SL Green Realty falls -10.1% - SL Green Realty is down -10.1%, or -$3.63 to $32.31.
|
CVNA | Hot Stocks12:00 EDT Carvana falls -11.6% - Carvana is down -11.6%, or -$6.50 to $49.30.
|
DFS | Hot Stocks12:00 EDT Discover falls -16.6% - Discover is down -16.6%, or -$20.27 to $101.58.
|
SEM | Hot Stocks12:00 EDT Select Medical rises 7.3% - Select Medical is up 7.3%, or $2.19 to $32.30.
|
STG | Hot Stocks12:00 EDT Sunlands Online rises 9.3% - Sunlands Online is up 9.3%, or 40c to $4.70.
|
OLO | Hot Stocks12:00 EDT Olo rises 9.3% - Olo is up 9.3%, or 63c to $7.35.
|
SAP | Hot Stocks11:51 EDT SAP trading halted, news pending
|
IZM | Hot Stocks11:44 EDT ICZOOM Group Inc trading resumes
|
UBSFY | Hot Stocks11:43 EDT Ubisoft sees Q2 net bookings around EUR 350M
|
IZM | Hot Stocks11:34 EDT ICZOOM Group Inc trading halted, volatility trading pause
|
UAL BA | Hot Stocks10:52 EDT United Airlines sees FY23 CapEx about $8.5B - Expects to take delivery 28 737 Max aircraft in Q3.
|
UAL | Hot Stocks10:45 EDT United Airlines: September, October demand 'looks strong' vs. 2019
|
PPG | Hot Stocks10:44 EDT PPG board approves 3c increase to dividend to 65c per share - The Board of Directors of PPG approved a 3c-per-share increase in the company's dividend, declaring a regular quarterly dividend of 65c per share, payable Sept. 12 to shareholders of record Aug. 10. This marks the company's 500th consecutive dividend payment, PPG said.
|
UAL | Hot Stocks10:41 EDT United Airlines currently in 'active negotiations' with flight attendants
|
UAL | Hot Stocks10:39 EDT United has adjusted down 2H23 capacity guidance, CEO says - Cites infrastructure constraints at its hubs, particularly Newark, CEO Scott Kirby says.
|
UAL | Hot Stocks10:38 EDT United saw 'one of the most challenging operating environments' in June - Comments taken from Q2 earnings conference call.
|
FCX | Hot Stocks10:28 EDT Freeport-McMoRan says balance sheet is 'solid' - Says focused on continued success in leach efforts. Says remains focused on cost management. Says has opportunity to add 200M lbs of copper a year with very little investment through North America staffing and asset efficiency. Says leaching is a 'major value opportunity' and 'major catalyst'. Says continuing to evaluate expansion of Bagdad mine. Says making progress with Kucing Liar block cave. Says looking at investments in Bagdad, El Abra. Says has a series of U.S. brownfield opportunities. Says continues to be disciplined in approach while executing on projects.
|
FCX | Hot Stocks10:15 EDT Freeport-McMoRan says copper demand is expected to double by 2035 - Says continues to work with Indonesian government. Says expects to receive formal approval to resume exports in coming days. Says expects to commence exports in late July. Says copper consumption continues to grow in China. Says ability of copper industry to meet demand is 'major challenge'.
|
FCX | Hot Stocks10:09 EDT Freeport-McMoRan says 'well-positioned' for 'strong' results in 2H23 - Says production results were strong across portfolio in Q2. Says financial flexibility remains in 'great shape'. Says making 'steady' progress on smelter in Indonesia. Says expects to complete construction by 2Q24. Reports ongoing 'progress' with leach initiative. Says confidence is increasing on significant upside for leach initiative.
|
FCX | Hot Stocks10:05 EDT Freeport-McMoRan says fundamentals in global copper market 'remain positive' - Says global copper inventories remain 'remarkably' low. Comments taken from Q2 earnings conference call.
|
SCYX | Hot Stocks10:00 EDT Scynexis, Hansoh Pharma announce NMPA acceptance of NDA for ibrexafungerp - SCYNEXIS announced that China's National Medical Products Administration has accepted for review a New Drug Application for oral ibrexafungerp tablets for the treatment of adult and post-menarchal pediatric females with vulvovaginal candidiasis in the Chinese mainland. The application was submitted by partner Hansoh Pharmaceutical Group Company and is based on positive results from Phase 3 studies in which ibrexafungerp successfully achieved statistically significant superiority over placebo for the primary and key secondary study endpoints. In February 2021, SCYNEXIS entered into an agreement for the development and commercialization rights for oral ibrexafungerp in the greater China region with Hansoh Pharma. Under the terms of the agreement, Hansoh is responsible for the development, regulatory approval and commercialization of ibrexafungerp in Greater China. Ibrexafungerp, once approved, is expected to become a new, first in class anti-fungal treatment for Chinese patients with vulvovaginal candidiasis.
|
INFY | Hot Stocks10:00 EDT Infosys falls -10.0% - Infosys is down -10.0%, or -$1.77 to $15.94.
|
EFX | Hot Stocks10:00 EDT Equifax falls -10.5% - Equifax is down -10.5%, or -$24.95 to $212.54.
|
DFS | Hot Stocks10:00 EDT Discover falls -13.3% - Discover is down -13.3%, or -$16.25 to $105.60.
|
SOXS | Hot Stocks10:00 EDT Direxion Daily Semiconductor Bear 3X Shares rises 6.1% - Direxion Daily Semiconductor Bear 3X Shares is up 6.1%, or 54c to $9.35.
|
OLO | Hot Stocks10:00 EDT Olo rises 6.8% - Olo is up 6.8%, or 46c to $7.18.
|
SEM | Hot Stocks10:00 EDT Select Medical rises 8.3% - Select Medical is up 8.3%, or $2.50 to $32.62.
|
ABT | Hot Stocks09:58 EDT Abbott saw 'very strong growth' across all four sectors in Q2 - Says growth "broad-based" across geographies. Cites new product launches. Says pipeline is delivering "pretty significantly." Sees opportunity for gross margin expansion. Says "well set up" for 2H23 and into 2024.
|
BHLB | Hot Stocks09:47 EDT Berkshire Hills Bancorp falls -7.4% - Berkshire Hills Bancorp is down -7.4%, or -$1.76 to $22.13.
|
INFY | Hot Stocks09:47 EDT Infosys falls -10.6% - Infosys is down -10.6%, or -$1.88 to $15.84.
|
DFS | Hot Stocks09:47 EDT Discover falls -12.7% - Discover is down -12.7%, or -$15.53 to $106.32.
|
PGRU | Hot Stocks09:47 EDT PropertyGuru rises 5.2% - PropertyGuru is up 5.2%, or 22c to $4.47.
|
OLO | Hot Stocks09:47 EDT Olo rises 5.7% - Olo is up 5.7%, or 38c to $7.10.
|
SOXS | Hot Stocks09:47 EDT Direxion Daily Semiconductor Bear 3X Shares rises 5.9% - Direxion Daily Semiconductor Bear 3X Shares is up 5.9%, or 52c to $9.33.
|
AMZN | Hot Stocks09:40 EDT Amazon to launch pay-by-palm technology at all Whole Foods stores this year - Amazon is bringing its pay-by-palm system to all of its Whole Foods stores by the end of the year, the company announced Thursday. Amazon One lets users enter and pay for items in stores by swiping their hand over a kiosk. The company said: "Amazon One simplifies everyday interactions. It's a free, contactless service that lets you use your palm to pay, enter, or identify yourself." Reference Link
|
JNJ | Hot Stocks09:38 EDT J&J CEO says Abiomed integration 'going really well' - J&J's CEO says continuing to look for opportunities in M&A, including in MedTech and Pharma, adding that the company is "not averse" to transactions of "larger size."
|
NVEC | Hot Stocks09:36 EDT NVE Corp. trading resumes
|
WYY | Hot Stocks09:32 EDT WidePoint awarded $3.2M mobility managed services contract - WidePoint announced that it was awarded a $3.2 million contract for wireless mobility services by the Federal Communications Commission. The period of performance is one-year base phase followed by four-year option periods.
|
NVEC | Hot Stocks09:31 EDT NVE Corp. trading halted, volatility trading pause
|
VZ | Hot Stocks09:29 EDT Verizon completes proof of concept for multi-unit internet solution - Verizon has completed a proof of concept in Texas showcasing a new multi-unit internet solution which could expand the addressable homes and businesses that can be served with its vast mmWave spectrum holdings. Specifically designed for multi dwelling units and distributed enterprise campuses and high rises, this point to multipoint architecture leverages Verizon's mmWave high band spectrum holdings, owned fiber infrastructure and existing Intelligent Edge metro and core infrastructure to provide reliable, secure, multipoint connections from a single donor cell site. The recent demonstration showcased an architectural design that is less expensive to build, quicker to deploy, and addresses the unique complexities of distributed end users in a single facility or small area such as a residential unit with a large population. In this proof of concept, an airlink over licensed mmWave spectrum was established between a centralized, rooftop radio site and a radio atop a simulated multi end-point building. The signal was then transmitted via coaxial cable throughout the building to a data processing unit along with a corresponding modem. From there, the building's existing wiring transported the signal to end user routers that provided broadband coverage throughout simulated distributed end points. Instead of transmitting the data through Verizon's 4G and 5G wireless cores, this unique architecture uses a simplified Broadband Network Gateway to direct the traffic to and from the internet over Verizon's public IP network. This means that data traffic will not add load on Verizon's current wireless cores while at the same time providing excellent capacity and latency.
|
AAL | Hot Stocks09:26 EDT American Airlines says 'real interest' in taking care of pilots
|
ME | Hot Stocks09:25 EDT 23andMe releases Simvastatin Medication Insight report - 23andMe Holding released a new Simvastatin Medication Insight report as part of its 23andMe+ membership service that reports on a person's likelihood of experiencing side effects from this commonly prescribed statin drug. The new Medication Insight report is part of a suite of 23andMe reports that examine how a person's genetics may impact their response to certain medications and their chance of experiencing possible side effects. These are the first and only direct-to-consumer pharmacogenetic reports authorized by the FDA. Under the recent FDA 510(k) clearance, which modifies the labeling of the previously authorized SLCO1B1 Drug Transport report, there is no additional confirmatory testing requirement for this report, and a healthcare provider can use the results from the report to guide care. Simvastatin is a commonly prescribed statin drug used to lower cholesterol in the blood and reduce the risk of heart attacks, strokes, or other heart problems. This new Simvastatin Medication Insight report available for 23andMe+ members looks at how individuals respond to simvastatin, known by the brand names such as Flolipid and Zocor. The insight report provides clear information about whether an individual has an increased chance of experiencing side effects.
|
JNJ | Hot Stocks09:24 EDT J&J CFO says capital allocation priorities aren't changing - J&J's CFO says in terms of M&A that the company will "always be on the hunt for real good strategic opportunities" and is "looking feverishly as we always do across MedTech and Pharm."
|
ACHR UBER | Hot Stocks09:21 EDT Archer Aviation hires Uber Elevate co-founder, Nikhil Goel as CCO - Archer Aviation (ACHR) announced Nikhil Goel has joined as the company's Chief Commercial Officer. Goel will lead the execution of Archer's global commercialization efforts as the company prepares to bring Midnight to market in 2025 in the U.S. in partnership with United Airlines. Goel brings deep industry expertise to Archer after co-founding Uber (UBER) Elevate, Uber's air taxi division, and jointly authoring the Uber Elevate white paper that is widely credited with establishing the vision for the commercial eVTOL aircraft industry. As Chief Commercial Officer, Goel will be responsible for spearheading Archer's commercialization strategy with a focus on bringing New York, Chicago, Los Angeles, Miami and San Francisco online as Archer's initial domestic markets and capturing international demand by stewarding partnership opportunities across several key markets, including the Middle East, Asia, and Latin America. Goel's addition is timely as Archer is continuing to rapidly advance its commercialization efforts after receiving a $10M pre-delivery payment from United Airlines for 100 eVTOL aircraft that it anticipates deploying into the multiple point-to-point routes it has announced alongside United in the U.S.
|
ACHR UBER | Hot Stocks09:21 EDT Archer Aviation hires Uber Elevate co-founder, Nikhil Goel as CCO - Archer Aviation (ACHR) announced Nikhil Goel has joined as the company's Chief Commercial Officer. Goel will lead the execution of Archer's global commercialization efforts as the company prepares to bring Midnight to market in 2025 in the U.S. in partnership with United Airlines. Goel brings deep industry expertise to Archer after co-founding Uber (UBER) Elevate, Uber's air taxi division, and jointly authoring the Uber Elevate white paper that is widely credited with establishing the vision for the commercial eVTOL aircraft industry. As Chief Commercial Officer, Goel will be responsible for spearheading Archer's commercialization strategy with a focus on bringing New York, Chicago, Los Angeles, Miami and San Francisco online as Archer's initial domestic markets and capturing international demand by stewarding partnership opportunities across several key markets, including the Middle East, Asia, and Latin America. Goel's addition is timely as Archer is continuing to rapidly advance its commercialization efforts after receiving a $10M pre-delivery payment from United Airlines for 100 eVTOL aircraft that it anticipates deploying into the multiple point-to-point routes it has announced alongside United in the U.S.
|
XXII | Hot Stocks09:21 EDT 22nd Century regains compliance with Nasdaq listing standards - 22nd Century Group has regained compliance with Nasdaq listing requirements. In a letter dated July 19, 2023, Nasdaq informed the Company that it has achieved compliance with the minimum bid price rule required for continued listing on the Nasdaq Capital Market.
|
ATOS | Hot Stocks09:18 EDT Atossa receives Health Canada approval for Phase 2 EVANGELINE trial - Atossa Therapeutics announced that Health Canada has issued a "No Objection Letter" following the Company's Clinical Trial Application for its Phase 2 EVANGELINE study. This means Atossa can open sites and enroll patients in their Phase 2 EVANGELINE study throughout Canada. The ongoing Phase 2 EVANGELINE study is a randomized non-inferiority trial of Atossa's patented Selective Estrogen Receptor Modulator, (Z)-endoxifen, and exemestane plus goserelin as a neoadjuvant treatment for pre-menopausal women with Grade 1 or 2 Estrogen Receptor positive / Human Epidermal Growth Factor Receptor 2 negative breast cancer. Participants will receive neoadjuvant treatment for up to six months, followed by surgery. The primary objective of the EVANGELINE study is to evaluate the endocrine sensitive disease rate, measured by Ki-67, after four weeks of treatment with (Z)-endoxifen compared to treatment with current standard of care, exemestane plus goserelin. The study is expected to enroll approximately 175 patients at sites across the United States and Canada.
|
AAL | Hot Stocks09:18 EDT American Airlines says no fleet replacement needs through end of decade - Says only growth aircraft requirements. Says biggest opportunity is getting regional fleet up and running.
|
JNJ | Hot Stocks09:17 EDT Johnson & Johnson CEO says 'nothing has changed' with respect to MARIPOSA study
|
EDBL WMT | Hot Stocks09:16 EDT Edible Garden, Walmart expand distribution agreement - Edible Garden (EDBL) announced an expansion of the Company's distribution alliance with Walmart (WMT). The initiative includes providing additional SKUs in Walmart locations across the Northeast and broadening Edible Garden's reach to retail locations in the East South Central region of the United States.
|
JNJ | Hot Stocks09:16 EDT J&J says will be 'back in the torte system' if judge dismisses bankruptcy claims - Johnson & Johnson says if its talc-related bankruptcy plans are not approved it will be "back in the torte system" and plans to defend itself "aggressively" and successfully defend against the "vast majority of claims" if that turns out to be the case. Johnson & Johnson is speaking about its talc-related legal plans during its earnings call.
|
WAVE | Hot Stocks09:12 EDT Eco Wave Power visits Greece to analyze potential 2MW wave energy power station - Inna Braverman, CEO of Eco Wave Power Global traveled to Greece for an official site visit of the Heraklion breakwater in Crete, which is currently being analyzed for a potential 2MW wave energy power station. During the visit, the representatives from Eco Wave Power and Rogan Associates S.A. inspected the breakwater at the Port of Heraklion, from both the shore and the seaside, and held meetings with the managing director at Heraklion Port Authority A.E., Minas Papadakis, and other port representatives, to provide updates regarding the milestones achieved so far in the planning of the project. The next steps of the project will be to conduct further studies and analyses of the site, with Rogan Associates S.A. focusing on the civil engineering and pricing for a 2 MW installation, and Eco Wave Power working on the detailed project design. In April Eco Wave Power entered into an agreement with Rogan Associates to bring Eco Wave Power's technology design to Greece for the first time. According to the collaboration agreement, Rogan Associates is reinforcing the existing breakwater and planning the potential extension of the breakwater. In addition to the completion of the wave energy production analysis, Eco Wave Power will custom-design its wave energy technology to retrofit the existing breakwater at the Port. This work conducted by the parties is funded as part of a grant received by Rogan Associates and Heraklion Port Authority from the European Union Climate, Infrastructure, and Environment Executive Agency.
|
JNJ | Hot Stocks09:11 EDT Johnson & Johnson to seek appeal of talc case based on 'erroneous' rulings - Johnson & Johnson is speaking about its plans to appeal the talc case ruling during its earnings call. The verdict award will not be paid during the bankruptcy process and this recent ruling has "absolutely no impact on that process," the company added.
|
BLNK | Hot Stocks09:09 EDT Blink Charging provides over 4,000 dealerships with EV charging products - Blink Charging announced the Company is now engaged with more than 4,000 automotive dealers in the US, Europe, Latin America and Asia Pacific for purchase, installation and ongoing management of EV charging equipment and services. During the first quarter of 2023, Blink successfully secured more than 600 agreements with dealers globally, and foresees further growth throughout 2023 as leading auto manufacturers unveil new models and experience increased sales. Since 2020, Blink has sold or deployed over 950 DC Fast Chargers along with more than 7,500 Level 2 chargers to address the multiple needs dealers have in keeping vehicles charged and ready for customers. "Dealers are the driving force behind the electrification of the auto industry and play a pivotal and dynamic role in driving forward the progress and acceptance of EV technology," said Mike Battaglia, Chief Revenue Officer for Blink Charging. "At Blink, we are dedicated to assisting dealers throughout the entire process of introducing EV charging into their businesses. From the initial stages of project inception to charger commissioning, and ongoing technical and customer support, Blink is trusted by OEMS and dealers as a reliable and valuable resource as they increasingly embrace electrification."
|
WRAP | Hot Stocks09:08 EDT Wrap Technologies announces widespread adoption of BolaWrap 150 - Wrap Technologies announces the widespread adoption of their BolaWrap 150 technology by law enforcement agencies. The company's commitment to a no-harm approach to law enforcement has garnered significant support from officers and communities alike. "We take pride in providing cutting-edge technology that prioritizes public safety and aligns with the needs of our customers," said Kevin Mullins, Chief Executive Officer of Wrap Technologies. "BolaWrap 150 is a testament to our commitment to listening to our customers and advancing law enforcement solutions responsibly." Mullins emphasized, "Our platform approach ensures we can swiftly deliver technological advancements to our customers, empowering officers with the tools they need to prioritize public safety. As law enforcement agencies continue to embrace the BolaWrap 150 solution, Wrap Technologies remains committed to refining their innovative products, making communities safer for all."
|
PMBHF | Hot Stocks09:08 EDT PharmAla Biotech receives MHRA guidance on ALA-002 - PharmAla Biotech Holdings announced, following pre-submission meetings held in Q1 of 2023, it has received written guidance from the UK's Medicines and Healthcare products Regulatory Agency's. The guidance constitutes, in part, advice that ALA-002 does not require further preclinical data in order for clinical trials to proceed. "While this result took a bit longer to receive than we anticipated, it did conform with our expectations," said Dr. Harpreet Kaur, Vice President of Research, PharmAla Biotech. "We are now prepared to move into the clinical phase of ALA-002's development with full confidence that we have a range of competent and well-regulated jurisdictions to choose from. Our intent is to move rapidly, with the expectation of moving into a Phase 2 trial." Following receipt of this guidance, PharmAla is further pleased to announce that it has entered into a clinical development agreement with the University of Sydney, under the leadership of Dr. Adam Guastella, the Michael Crouch Chair in Child and Youth Mental Health at the University.
|
TURN | Hot Stocks09:07 EDT 180 Degree Capital reports $6.22 preliminary NAV as of June 30 - "We decided to pre-announce our net asset value per share for Q2 2023 due primarily to the weakness in TURN's stock and the disconnect between share price and NAV," said Kevin Rendino, CEO of 180. "While we are frustrated with our performance in Q2 2023, we used the quarter to position TURN to benefit should certain catalysts of our holdings occur down the road. Our current belief is that some of these catalysts could materialize over the ensuing months. These catalysts primarily center around removal of capital structure overhangs through refinancing of debt, completion of strategic transactions, and/or certain companies demonstrating better corporate governance and alignment with all stakeholders. We currently believe that these catalysts, if they occur, could result in material appreciation of the value of our holdings in these companies in line with our initial investment target of at least 100%. We continue to use our constructive activism to drive these events to completion where possible." Our underperformance this quarter following outperformance last quarter was primarily due to declines in value of certain of our larger holdings and led to a gross total return of our public investments of -5.8% versus +5.3% return for the Russell Microcap Index," noted Daniel B. Wolfe, President of 180. "Company specific events at Intevac and continued weakness in the price per share of Comscore, even with significant improvements in its business-were large contributors to declines in our NAV. Strength in our holdings of Commercial Vehicle Group and Potbelly Corporation, coupled with renewed interest in D-Wave Quantum, due to its position in enabling artificial intelligence platforms, were not enough to offset our declining positions. We ended the quarter with liquid public investments representing nearly 90% of our net assets. Management continues to believe that TURN's stock does not reflect the appropriate value of the company and its holdings. As such management continued to purchase TURN in the open market in the quarter, in addition to the significant repurchase by TURN of its stock in May 2023. We believe there is no justification, despite being 280 basis points behind the Russell Microcap Index YTD, that TURN's stock price warrants an almost 30% discount to our NAV at the end of Q2 2023. Since our inception, we have generated a gross total return of +223.6% versus +47.1% for the Russell Microcap Index. Q3 2023 has started off positively for TURN and its holdings. We run a highly concentrated portfolio and our returns will always be dependent on the companies we own and not only what happens with market indices. While this period has been maddening and difficult to wade through, we believe the inherent value of the totality of our holdings can lead to a material increase in our NAV over time. We look forward to discussing these results with our shareholders and other interested parties on our Q2 2023 quarterly update call that we currently expect to hold in early-to-mid-August 2023."
|
APCX | Hot Stocks09:07 EDT AppTech Payments signs 6-part media contract on interviews with FMW Media - FMW Media's business TV show, New to The Street, announces the signing of a 6-part media contract on filming and broadcasting tailored interviews about AppTech Payments Corp.'s corporate fundamentals. Luke D'Angelo, CEO and Chairman, AppTech states, "I'm excited to work with the highly professional experts at New to The Street while they begin to market our Company through their national TV media network. We at APCX believe the upcoming televised interviews can inform viewers about our Company's unique and transformative payment solutions. Our Fintech cloud-based patented platform Commerse (TM) is changing the legacy payment and banking industries. I look forward to explaining how it works and how our clients have become more efficient in their transactions. The show should provide our Company an effective way to reach potential investors and end-users alike."
|
KDP | Hot Stocks09:06 EDT Keurig Dr Pepper to acquire 33% ownership of La Colombe for $300M - Keurig Dr Pepper and La Colombe announced a strategic partnership, including a long-term sales and distribution agreement for La Colombe ready-to-drink coffee and a long-term licensing, manufacturing and distribution agreement for La Colombe branded K-Cup coffee pods. Keurig Dr Pepper will also make an equity investment in La Colombe, enabling KDP to participate in the value creation upside expected from the partnership. La Colombe is an independent, high-growth, super premium coffee company that serves consumers across multiple channels, including the retail trade, branded cafes, foodservice and direct to consumer. Under the long-term sales and distribution agreement, KDP will sell and distribute shelf-stable La Colombe RTD coffee beverages in KDP's direct store distribution network, which is expected to drive meaningful growth in the brand's availability across these mainstream retail channels. In addition, KDP will manufacture, sell and distribute La Colombe branded K-Cup coffee pods, under a license agreement, in the U.S. and Canada. KDP will make a cash investment in La Colombe of $300M, in exchange for a 33% ownership stake in the company, making KDP the second largest investor in La Colombe behind its majority owner and Chairman, Hamdi Ulukaya. La Colombe plans to use the proceeds to accelerate growth and pay off debt. KDP's investment in La Colombe represents a multiple of approximately 3.0X estimated 2024 consolidated net sales. The transition of La Colombe ready-to-drink coffee distribution to KDP will begin in late 2023, while the launch of La Colombe branded K-Cup pods will occur during 2024. The equity investment, which is subject to regulatory approval, is expected to close by the end of the Q3.
|
GOVX | Hot Stocks09:06 EDT GeoVax Labs initiates Phase 2 trial of COVID-19 vaccine booster in CLL - GeoVax Labs announced the start of an investigator-initiated clinical trial, titled "Randomized observer-blinded phase 2 trial of COVID-19 booster with GEO-CM04S1 or Pfizer-BioNTech Bivalent vaccine in patients with chronic lymphocytic leukemia, CLL," at City of Hope National Medical Center, led by Alexey Danilov, M.D., PhD as principal investigator. The primary immune response outcome will be 56 days following the first booster injection. Up to 40 participants will be treated in each arm, with immune responses evaluated at the interim and final analyses in each arm. David Dodd, GeoVax President, and CEO, added, "We are excited to begin this third important study for CM04S1 and look forward to sharing progress reports as we advance. We believe the CM04S1 vaccine, containing the two antigens, S and N, along with the recognized antibody and cellular immune responses resulting from the MVA approach, has the potential to offer greater booster protection than that from the current vaccines in use, as well as provide a greater degree of protection within immunocompromised patients."
|
RCAT | Hot Stocks09:04 EDT Red Cat's Teal 2 sUAS available for purchase through U.S.'s GSA Advantage - Red Cat announces that its military-grade sUAS, the Teal 2, is now available for purchase through the U.S. government's GSA Advantage website. GSA Advantage is an online shopping and ordering service created within the General Services Administration for use by government agencies to buy commercial products and services. "The Teal 2's compact size, advanced technology and rugged design make it ideal for the needs of the warfighter, though it's versatile enough that other federal agencies, including U.S. Customs and Border Protection, have become early-adopter customers," said Geoff Hitchcock, senior vice president of global defense solutions at Red Cat. "We're proud to now be able to directly offer the Teal 2 for sale to all U.S. government agencies through GSA Advantage."The Teal 2 is manufactured at Red Cat's purpose-built factory in Salt Lake City, Utah.
|
BCOV PUBM | Hot Stocks09:04 EDT Brightcove enters agreement with PubMatic for ad monetization - Brightcove (BCOV) announced it has entered into a strategic agreement with PubMatic (PUBM). The partnership combines PubMatic's programmatic advertising solutions with Brightcove's video platform to enhance and bolster demand for the recently launched Brightcove Ad Monetization, a service designed to help media companies better monetize their content.
|
CTMX | Hot Stocks09:03 EDT CytomX Therapeutics announces new employment inducement grants - CytomX Therapeutics announced that on July 19, 2023, the Company granted its recently appointed Senior Vice President, Chief Medical Officer, Yu-Waye Chu, M.D., an option to purchase 375,000 shares of the Company's common stock and also granted an additional new employee options to purchase 2,500 shares of the Company's common stock, at an exercise price per share equal to $1.82, which was the closing trading price on July 19, 2023, the date of the grants. The stock options were granted pursuant to the Company's 2019 Employment Inducement Incentive Plan, which was approved by the Company's board of directors in August 2020 under Rule 5635(c)(4) of The Nasdaq Global Market for equity grants to induce new employees to enter into employment with the Company.
|
JNJ KVUE | Hot Stocks09:03 EDT J&J says to provide 'timely' new guidance when no longer Kenvue majority holder - Johnson & Johnson CFO Joe Wolk continues speaking on the company's Q2 earnings call.
|
NN | Hot Stocks09:03 EDT NextNav confirms successful initial tests of accurate 3D PNT service - NextNav has announced that it has successfully tested its positioning and timing solution that combines the company's assured PNT, position, navigation and timing, TerraPoiNT system with existing LTE and 5G network signals. The test, which took place in and around San Jose, California, demonstrates how TerraPoiNT signals can be integrated with existing cellular signals to deliver accurate 3D positioning and timing information that is not reliant on conventional satellite-based GPS and GNSS signals. "Whether its utilities, banks, data centers, transportation, or emergency services, critical infrastructure today is reliant on GPS for position, navigation and timing services, making it highly vulnerable to GPS as a single point of failure" said Ganesh Pattabiraman, Co-Founder and CEO of NextNav. "With this integration we have demonstrated a highly scalable and lower cost alternative - a 3D PNT solution which overcomes the vulnerabilities of GPS with a complementary ground based resilient PNT layer that extends PNT capabilities in urban and indoor environments ."
|
AAL UAL | Hot Stocks09:02 EDT American Airlines expects to match wages United is proposing for pilots
|
CANB | Hot Stocks09:02 EDT Can B Corp. secures 1.8M lbs. of biomass for awarded contract - Can B announced its newly awarded contract with One Bad Moon Rising and purchase of 1.8 million pounds of biomass. To initially service the contract, Can B purchased 1.8 million pounds of biomass that is ready for immediate processing. The biomass is stored indoors in 1,000-pound supersacks in Ft. Morgan, Colorado.
|
AVPT MSFT | Hot Stocks09:02 EDT AvePoint expands 20-year Microsoft relationship with Microsoft 365 Backup - AvePoint (AVPT) announced the evolution of its Cloud Backup offering and the latest milestone in its 20-year partnership with Microsoft (MSFT), working with them to integrate with Microsoft 365 Backup. As one of first providers to integrate with the Microsoft 365 Backup API, AvePoint now provides a more sophisticated approach to protecting and quickly restoring customer and partner data in the event of a malicious attack or accidental data deletion. Integrating with the Microsoft 365 Backup API strengthens AvePoint Cloud Backup for Microsoft 365, Dynamics 365, Azure Active Directory and Virtual Machines to provide organizations with a complete, end-to-end backup solution that enables them to own their service level agreements, protect their most critical data and maintain flexibility in where data is stored. "We're excited about working with AvePoint, and we're looking forward to the unprecedented speed and scale of backup and restore experiences they can bring to customers with our new Microsoft 365 Backup solution," said Jeff Teper, President, Collaboration Apps and Platforms, Microsoft.
|
JNJ KVUE | Hot Stocks09:01 EDT J&J says launch of Kenvue exchange offer could come as soon as 'coming days' - Johnson & Johnson CFO Joe Wolk made the comments while speaking on the company's Q2 earnings call.
|
AAL | Hot Stocks08:59 EDT American Airlines expects to 'preserve' current margin trajectory - Does not expect any "material change" to financial outlook from NEA end. "Encouraged" with overall level of demand and expects it to continue, although some seasonality in U.S. Has not seen a deceleration in travel demand yet. Views competitive landscape "very favorably."
|
OFED | Hot Stocks08:57 EDT Oconee Federal Financial Corp to delist common stock from Nasdaq - Oconee Federal Financial Corp announced that it has notified Nasdaq of the company's intent to voluntarily delist its common stock from Nasdaq. The company further intends to withdraw the registration of its common stock with the SEC under the Securities Exchange Act of 1934, as amended.
|
FCX | Hot Stocks08:53 EDT Freeport-McMoRan sees Q3 copper sales 1.03B lbs - Sees Q4 copper sales 1.125B lbs. Sees Q3 gold sales 420,000 ozs, sees Q4 sales 565,000 oz. Sees Q3 Moly sales 20M lbs, sees Q4 sales 20M lbs.
|
AMPX BAESY | Hot Stocks08:50 EDT Amprius' batteries power first stratospheric flight for BAE Systems drone - Amprius Technologies (AMPX) announced that its high-density batteries played a significant role in powering BAE Systems' (BAESY) first successful stratospheric flight trial. PHASA-35, the High-Altitude Pseudo Satellite HAPS Uncrewed Aerial System designed by BAE Systems' subsidiary Prismatic Ltd., is planned to operate above the weather and conventional air traffic. During a recent test flight, the PHASA-35 crossed an altitude of more than 66,000 feet, reaching the stratosphere, before landing successfully. The trial, completed last month in New Mexico, allowed engineers to assess the experimental solar-electric drone within the edges of the planet's atmosphere. "Amprius is proud to be recognized as a key partner to BAE Systems supporting their development of the PHASA-35(R)," said Dr. Kang Sun, Chief Executive Offer of Amprius. "This ultralight platform provides an alternative and flexible approach to traditional systems such as satellites or conventionally powered aircraft. As we develop our next-generation of industry-leading silicon anode batteries, we look forward to helping BAE Systems and Prismatic further enhance the capabilities of their PHASA-35 aircraft."
|
CYTO | Hot Stocks08:49 EDT Altamira Therapeutics, Pharma Nordic enter exclusive agreement for Bentrio - Altamira Therapeutics has entered into an exclusive agreement with Pharma Nordic AS for the marketing and distribution of Bentrio, a nasal spray for protection against airborne allergens, in Norway and potentially further Scandinavian countries. The collaboration agreement will allow Pharma Nordic to market and commercialize Bentrio in Norway beginning in the first quarter of 2024, and, subject to meeting certain milestones, also in Sweden, Finland, and Denmark later on.
|
GDYN | Hot Stocks08:48 EDT Grid Dynamics enters Microsoft's Azure Migration and Modernization Program - Grid Dynamics Holdings announced its entry into Microsoft's Azure Migration and Modernization Program. This innovative partnership program helps accelerate and simplify clients' migration & modernization of cloud workloads and includes a range of training, services, and financial support for transformation programs. As a member of this exclusive program, Grid Dynamics enables its clients to accelerate time to value on cloud transformation programs-freeing up investment for more advanced & disruptive digital transformation projects with Grid Dynamics.
|
ITI | Hot Stocks08:47 EDT Iteris awarded new $1M contract by Seminole County, Florida - Iteris he world's trusted technology ecosystem for smart mobility infrastructure management announced that it has been awarded a new $1M contract by Seminole County, Florida for a regional traffic signal retiming program, representing continued demand for Iteris' specialized consulting services in a key geographic market. Iteris Awarded Contract for Seminole County Traffic Signal Retiming Program The five-year Arterial Corridor Signal Retiming program includes data collection and analysis, development of signal timing plans, deployment, fine tuning in the field and performance evaluation. It will impact 19 systems and 146 intersections throughout the county.
|
CELTF | Hot Stocks08:47 EDT Centamin announces agreement for Egyptian mining regulatory framework - Centamin announces that the framework for the model mining exploitation agreement has been agreed in principle with the Egyptian Ministry of Petroleum & Natural Resources and the Egyptian Mineral Resources Authority. The MMEA sets out the legal and fiscal framework that will apply to commercial discoveries made on the highly prospective c.3,000km2 of ground awarded to Centamin in 2021 for exploration in the Eastern Desert of Egypt. Alongside industry partners, Martin Horgan, Centamin CEO, and the Egyptian Minister of Petroleum & Natural Resources, His Excellency Eng Tarek El-Molla, have jointly reached an agreement in principle on the fiscal and regulatory terms associated with the exploitation phase of new mining projects in Egypt. Following routine Egyptian government and legal procedures, the MMEA will be ratified as a Special Law by the Arab Republic of Egypt in late 2023. The MoP has been clear in its vision to create a thriving mining industry for the benefit of Egypt and its people. Centamin shares this vision and strongly believes that mining can fulfil its true potential in Egypt through employment, education and training, and direct financial and infrastructure investment to support the MoP's target for the mining industry to contribute 5% of the country's GDP by 2030.
|
KTTA | Hot Stocks08:45 EDT Pasithea Therapeutics to commence $4M tender offer for common stock - Pasithea Therapeutics announced that its Board of Directors has authorized the repurchase, through a $4.0 million tender offer, of up to approximately 5.7 million shares of the Company's outstanding common stock, at an anticipated cash purchase price of $0.70 per share. Pasithea's executive officers and directors have informed the Company that they do not intend to tender any shares of common stock in the Tender Offer. To the extent the Tender Offer is oversubscribed, the Company will accept shares for purchase in the Tender Offer on a pro rata basis. Pasithea anticipates consummating the Tender Offer during the third quarter of 2023.
|
AAL | Hot Stocks08:45 EDT American Airlines says 'on track' to deliver on FY guidance given in January
|
AAL | Hot Stocks08:45 EDT American Airlines sees FY23 capacity up 5%-8%
|
FCX | Hot Stocks08:44 EDT Freeport-McMoRan sees FY23 CapEx $3.2B excluding smelter projects - Sees 2023 copper sales 4B lbs., 2024 copper sales 4.2B lbs and 2025 copper sales 4.2B lbs. Sees 2023 gold sales 1.75M ozs, 2024 gold sales 1.8M ozs. and 2025 gold sales 1.6M ozs. Sees 2023 molybdenum sales 79M lbs., 2024 molybdenum sales 85M lbs. and 2025 molybdenum sales 90M lbs. Sees 2024 Capex $3.8B. Comments taken from presentation slides for Q2 earnings conference call.
|
AAL | Hot Stocks08:44 EDT American Airlines expects to take delivery of 23 new aircraft in 2023 - Sees FY23 aircraft CapEx $1.7B; non-aircraft CapEx $800M. Sees FY24 CapEx $3B-$3.5B. Expects near term CapEx to average $3.5B.
|
KTTA LSDI | Hot Stocks08:42 EDT Pasithea special committee rejects unsolicited bid from Lucy Scientific - Pasithea Therapeutics (KTTA) confirmed that an independent special committee of its Board of Directors thoroughly reviewed and rejected an unsolicited, non-binding proposal from Lucy Scientific Discovery (LSDI) to acquire all outstanding shares of Pasithea common stock for per share consideration consisting of $0.60 in cash plus $0.25 worth of Lucy common stock. After a comprehensive review, conducted in consultation with its independent financial and legal advisors, the Special Committee determined that the Lucy proposal does not reflect Pasithea's strategic value and prospects for continued growth and, as such, is not in the best interests of the Company or its stockholders.
|
OSS | Hot Stocks08:41 EDT One Stop Systems appoints Kalebaugh as VP of sales - One Stop Systems has appointed industry veteran and seasoned sales executive, Robert Kalebaugh, to the new position of vice president, VP, of sales. Kalebaugh brings to OSS more than 36 years of award-winning achievement in the development, marketing, and sales engineering of advanced technologies for the commercial and government markets.
|
JUPW | Hot Stocks08:40 EDT Jupiter appoints Gulyas to board of directors, Pascucci to advisory board - Jupiter Wellness announced the appointment of John Gulyas to its Board of Directors and Rich Pascucci to its Advisory Board. Both are formerly from GBB Drink Lab, creator of Safety Shot, the world's first rapid blood alcohol detoxification drink recently acquired by Jupiter Wellness. Currently, John is the CEO and founder of 2v consulting. Rich Pascucci is an active advisor with a wealth of leadership experience in the beverage industry. Currently, he is the owner of Black Apple Group.
|
LPLA | Hot Stocks08:40 EDT LPL Financial announces John Thornton, Jake Mclean join Linsco - LPL Financial announced that financial advisors John Thornton and Jake McLean have joined LPL's employee advisor channel, Linsco by LPL Financial, to launch Capitum Wealth Management. They reported having served approximately $245M in advisory, brokerage and retirement plan assets and join LPL from Wells Fargo Advisors.
|
ARRY | Hot Stocks08:39 EDT Array Technologies, Lock Joint Tube collaborate on new steel tube mill in Texas - Array Technologies entered into an agreement with Lock Joint Tube, a manufacturer of mechanical and structural-grade steel tubing, to secure supply from a new steel mill in Texas dedicated to manufacturing utility-scale solar tubing. Located in Temple, Texas, where Lock Joint Tube has established operations, the new mill will use locally sourced steel in the production of solar tubing in response to domestic content requirements in the Inflation Reduction Act. "Lock Joint Tube's newest mill will provide Array with domestic tubing under the IRA, which our customers are demanding in this high-growth market for utility-scale solar," said Kevin Hostetler, Chief Executive Officer at Array Technologies. "This investment in American manufacturing will provide jobs aligned with the renewable energy market to the local community, boost the integrity of the domestic solar supply chain, and support Array's continued expansion in the U.S., including in Texas and throughout the central U.S."
|
SGHT | Hot Stocks08:39 EDT Sight Sciences reports primary endpoint met in SAHARA trial - Sight Sciences announced the six-month results from the SAHARA randomized controlled trial. The trial successfully met its primary endpoint and the data reported statistically significant improvements as compared to Restasis eye drops for the treatment of dry eye disease. These results will be presented in greater detail at the American Academy of Optometry's annual meeting in October 2023. SAHARA Phase I Results: The SAHARA trial achieved its primary six-month endpoint, demonstrating the superiority of interventional eyelid procedures enabled by TearCare over Restasis eyedrops in the improvement of tear break up time, a key measure of aqueous retention, tear stability and the tear film's ability to protect the ocular surface. The SAHARA trial also observed that procedures enabled by TearCare were non-inferior to Restasis eyedrops in Ocular Surface Disease Index, which was the co-primary six-month endpoint. Throughout the study, interventional eyelid procedures with TearCare demonstrated clinically and statistically significant improvements of every endpoint and at every measurement interval: one week, one month, three months, and six months. Endpoints assessed include TBUT, meibomian gland score, corneal staining, and conjunctival staining. Symptoms endpoints include two commonly used patient-reported questionnaires: Ocular Surface Disease Index and Symptom Assessment in Dry Eye. TearCare is intended to help restore healthy function to diseased meibomian glands by removing obstructions interfering with meibum production and outflow. SAHARA is the first of its kind head-to-head, "device versus drug" RCT designed to compare the effectiveness of interventional eyelid procedures enabled by TearCare to twice daily Restasis prescription eyedrops. In this trial, 345 subjects at 25 sites in 14 states were randomized 1:1 between TearCare and Restasis groups. To reduce the potential for bias, physicians evaluating patients were masked regarding subject treatment groups. SAHARA was designed to challenge existing treatment paradigms by focusing physicians' attention on restorative procedures that address the underlying cause of meibomian gland disease and demonstrate the clinical benefits of procedural dry eye intervention compared to prescription dry eye eyedrops. An abstract of Phase 1 results from SAHARA has been accepted by the American Academy of Optometry for presentation at its annual meeting in October. Sight Sciences plans to submit the findings from SAHARA for publication in peer-reviewed journals in the coming months. In the next phase of the SAHARA study, subjects in the Restasis cohort cease use of Restasis, receive an interventional eyelid procedure with TearCare, and will be monitored for another six months. Subjects in the TearCare cohort will receive additional interventional eyelid procedures as necessary based on pre-determined criteria over an additional 18 months to measure the durability of procedural treatment effect. Final results from SAHARA are expected by 2025.
|
HOOD | Hot Stocks08:38 EDT Robinhood Money Drills partners with University of Memphis - As part of its flagship Robinhood Money Drills initiative, Robinhood Markets is partnering with the University of Memphis to launch a program to make financial education coursework available to the university's student-athletes. On July 20, 2023, Robinhood and the University of Memphis will host an on-campus event with University academic and athletic staff, alumni and student-athletes to celebrate the launch of the four-year long partnership. Robinhood will provide funding to support additional course sections of personal finance classes and offer guest lecturers to discuss financial education.
|
AAL | Hot Stocks08:37 EDT American Airlines says 'firing on all cylinders' - Says achieved all goals set out at start of the year. Says "very well positioned." Says "particular strength" in International travel heading into summer season. Says making "terrific progress" training pilots. Comments taken from Q2 earnings conference call.
|
SOPA | Hot Stocks08:36 EDT Society Pass's NusaTrip acquires Vietnam International Travel, Service JSC - NusaTrip, the online retail arm of Society Pass Incorporated, announces that it has acquired Vietnam International Travel and Service JSC, VIT, an IATA-licensed, full-service travel agency focused on marketing to the Vietnam inbound and outbound segments. NusaTrip previously acquired VLeisure, Vietnam's leading provider of hotel management and payment solutions, in April 2023. Patrick Soetanto, NusaTrip CEO, comments on the acquisition, "VIT is the first IATA-licensed travel acquisition we have made outside of Indonesia. Our business plan calls for acquisitions of other IATA-licensed travel agencies throughout Asia Pacific in 2023, including Philippines, Thailand, Singapore, Malaysia, Hong Kong, China, India and UAE, as we position NusaTrip to be the premier travel hub in SEA. According to Phocuswright, gross bookings in SEA by 2025 will reach 94% of the record 2019 level and digital transformation will accelerate rapidly across SEA, with online bookings more than doubling between 2022 and 2025. Effectively, the region has reverted back to pre-pandemic levels. We are growing NusaTrip at the opportune time."
|
VS | Hot Stocks08:35 EDT Versus Systems enters partnership with Maestro Media - Versus Systems announced that it has entered a strategic partnership with game creator Maestro Media to expand Versus' product portfolio and support Maestro Media's upcoming gaming campaigns. Versus' proprietary digital marketing platform will leverage existing Maestro Media campaigns and products to enhance both brand and consumer experiences as well as in-content rewards. "We are thrilled to work with tabletop gaming, IP and crowdfunding juggernaut Javon Frazier and his company to further develop the Winfinite platform and promote future Maestro Media products," said Matthew Pierce, Founder and CEO of Versus Systems. "Partnering with Maestro Media is a testament to the capabilities of Versus' marketing technology as Frazier has experience leading advertisement campaigns for legendary entertainment companies. Combining Winfinite's technology with Maestro Media's existing portfolio will allow brands to create marketing campaigns that are more engaging and rewarding than ever."
|
TTOO | Hot Stocks08:34 EDT T2 Biosystems receives FDA Breakthrough Device designation for C. auris test - T2 Biosystems announced the U.S. Food and Drug Administration, FDA, has granted Breakthrough Device designation for the Company's Candida auris, C. auris, direct-from-blood molecular diagnostic test. This marks the third T2 Biosystems' product to receive FDA Breakthrough Device designation, as the Company was previously granted FDA Breakthrough Device designation for its T2Resistance Panel and T2Lyme Panel. "We are pleased with the FDA's decision to grant Breakthrough Device designation for our Candida auris test, which provides greater and more frequent access to the FDA and may accelerate our path to FDA clearance," stated John Sperzel, Chairman and CEO of T2 Biosystems. "We believe adding Candida auris to the test menu on our FDA-cleared T2Dx Instrument will provide clinicians with a valuable tool to rapidly detect a dangerous, multidrug-resistant fungal pathogen much faster than blood culture-based methods, strengthening our value proposition and increasing the attractiveness of our products to U.S. hospitals."
|
PHUN | Hot Stocks08:33 EDT Phunware announces cost saving measures, reduces workforce by 33% - Phunware announced a series of strategic cost saving measures designed to improve its financial performance and to position it for sustainable, long-term success. The Company expects to realize annual run-rate cost savings upwards of $5. As part of its strategic cost optimization efforts, the Company has made the difficult but necessary decision to implement a reduction in force, impacting approximately 33% of Phunware's workforce across all departments. This decision is not a reflection on the dedication or performance of these team members, but rather a strategic action to refocus the Company's efforts on its most promising revenue generating opportunities and ensure Phunware's continued success in the rapidly evolving mobile technology landscape. In addition to the workforce reduction, Phunware is implementing several other cost-cutting measures to become a leaner and more efficient company. These include streamlining operations, reducing non-essential expenses, and optimizing use of existing resources to further enhance efficiencies.
|
SGBX | Hot Stocks08:32 EDT Safe & Green provides update on planned spinoff of SG DevCo - Safe & Green provided an update on the planned spinoff of Safe & Green Development Corp to become a standalone company listed on Nasdaq, and the process for distribution of SG DevCo shares to Safe & Green Holdings shareholders. As previously announced, the company plans to distribute 30% of SG DevCo to its current shareholders, with Safe & Green Holdings retaining 70%. A third-party fairness opinion has valued SG DevCo's fair market value at $74M. The company is awaiting final review and approval of the transaction by Nasdaq, which it expects to receive in the coming weeks. Once the transaction receives Nasdaq approval, the company will move forward with its plan to list SG DevCo on the Nasdaq exchange by announcing the record date and anticipated listing date, within approximately 30 days of Nasdaq's approval of the transaction. Safe & Green Holdings plans to distribute the shares of SG DevCo on the distribution date to holders of record as of the close of business on the yet-to-be-announced record date. The distribution is expected to be completed following the Nasdaq market closing on the Distribution Date. Safe & Green Holdings' transfer agent and registrar, American Stock Transfer and Trust Company, LLC, will serve as transfer agent and registrar for SG DevCo as well, and act as distribution agent in connection with the Distribution.
|
CMCSA | Hot Stocks08:31 EDT Nielsen announces renewal of agreement with Comcast - Nielsen announced a multi-year data license renewal agreement with Comcast Corporation. Under the terms of the agreement, Nielsen will expand its use of Comcast's return path data, or RPD, in its national and local television and cross-media measurement services via its de-duplicated, audience measurement solution, Nielsen One. Nielsen will also broaden its use of Comcast RPD for local TV measurement across all of the 94 media markets the two companies share. It is expected that the expansion of Nielsen's measurement using Comcast RPD will be introduced into the market in 2024.
|
TSLA | Hot Stocks08:30 EDT NHTSA: Tesla recalling 16,000 vehicles due to fault with seat belts - Tesla is recalling up to 15,869 2021-2023 Model S and Model X vehicles due to a fault with the seat belts, according to a NHTSA filing. Front-row seat belts may not be connected properly to the pretensioner anchors, which can cause the seat belts to detach, according to the filing. The company will also recall as many as 1,337 2023 Model S, Model X, and Model Y vehicles as the forward-facing camera may be misaligned.
|
PETV | Hot Stocks08:25 EDT PetVivo reports national distribution of Spryng to over 450 clinics - PetVivo Holdings is fastly approaching a milestone - the sale of its signature product Spryng with OsteoCushion to its 500th veterinary clinic. PetVivo has supplied this life enhancing product for companion animals to more than 450 clinics in 47 states.
|
SKYX MSFT | Hot Stocks08:22 EDT SKYX Platforms appoints Khadija Mustafa as senior tech, AI - SKYX Platforms announced that Khadija Mustafa - former AI and global business leader at Microsoft - has been appointed as a Senior Tech, AI and Global Business Advisor to SKYX. Mustafa has served in varying senior roles at Microsoft for the last 23 years spanning AI, Enterprise and Public Sector segments, hardware and devices, and supply chain. Her most recent position was Head of Global AI Sales, Customers & Partner Ecosystem in Industrial Metaverse Core, Cloud and AI Division.
|
ALL | Hot Stocks08:21 EDT Allstate announces estimated catastrophe losses for June of $1.01B - Allstate announced estimated catastrophe losses for the month of June of $1.01B or $799M, after-tax. June month catastrophe losses include 18 events estimated at $1.13B, with approximately 60% of the losses related to four wind and hail events, partially offset by favorable reserve reestimates for prior events. Total catastrophe losses for the second quarter were $2.7B, pre-tax. Unfavorable prior year reserve reestimates, excluding catastrophes, totaled $181M in the second quarter with approximately $148M related to National General brand, primarily driven by personal auto injury coverages, and approximately $31M related to litigation activity in the state of Florida. During the month of June, the Allstate brand implemented auto rate increases of 11.6% across 12 locations, resulting in total brand premium impact of 2.6%.
|
GRFS | Hot Stocks08:16 EDT Grifols announces its Phase 4 trial of XEMBIFY met its primary endpoint - Grifols announced that its recently concluded phase 4 trial evaluating a biweekly dosing of XEMBIFY has met its primary endpoint. It has demonstrated that patients with primary immunodeficiencies treated with this subcutaneous 20% immunoglobulin product every two weeks achieved non-inferiority in total Ig levels compared with those who received the medication weekly. The phase 4 trial also demonstrated similarly good safety and tolerability profiles between biweekly and weekly administration. It was a multicenter, single-sequence, open-label clinical study that included 27 subjects across 18 U.S. sites. Results will support the potential product labeling extension of XEMBIFY to include biweekly dosing, pending review and approval by the United States Food and Drug Administration. This option is already available in the European markets where it is authorized.
|
GRNA | Hot Stocks08:15 EDT GreenLight Bioscences announces expiration of tender offer period - GreenLight Biosciences is initiating the final steps in closing its previously announced merger with SW MergerCo and SW ParentCo. Following the completion of the Merger, shares of GreenLight common stock are expected to cease trading on the NASDAQ Global Market after market close on July 20, 2023, and will no longer be listed for trading on the NASDAQ. Merger Sub's tender offer to purchase any and all outstanding shares of GreenLight's common stock expired one minute after 11:59 p.m. on July 19, 2023. As of one minute after 11:59 p.m. on July 19,2023, a total of 18,791,264 shares of GreenLight common stock were validly tendered and not validly withdrawn pursuant to the Offer, representing approximately 60.4% of the outstanding shares of GreenLight common stock not otherwise owned by Merger Sub, its affiliates or the Rollover Stockholders. In addition, "Notices of Guaranteed Delivery" have been delivered for 477,399 shares of GreenLight common stock, representing approximately 1.5% of the outstanding shares not otherwise owned by Merger Sub, its affiliates or the Rollover Stockholders. Merger Sub intends to accept for payment in accordance with the terms of the Offer all shares of GreenLight common stock that were validly tendered and not validly withdrawn as of the expiration of the Offer. Merger Sub will be merged with and into GreenLight, with GreenLight continuing as the surviving corporation that is wholly owned by the Parent. Each remaining share of GreenLight common stock not purchased in the Offer will be converted into the right to receive $0.30 in cash, without interest, and subject to deduction for any required withholding taxes.
|
CMRA | Hot Stocks08:14 EDT Comera Life Sciences announces collaboration with QCL - Comera Life Sciences announced a partnership with Quality Chemical Laboratories, QCL, to manufacture one of Comera's lead SQore excipients, as part of a broader strategy to secure the GMP manufacturing and supply chain of key proprietary technology owned by the Company. "QCL is pleased to leverage its strong synthetic and analytical chemistry expertise to advance Comera's technology platform," said Dr. Yousry Sayed, President and CEO of QCL. "There has been a growing trend towards bringing back manufacturing of critical, high-value technologies such as pharmaceuticals to the United States to reduce supply risk, ensure high quality production and improve regulatory compliance. We are pleased to work with Comera on this important initiative to help them secure the supply, distribution and quality of their key technologies."
|
SGMO | Hot Stocks08:14 EDT Sangamo, Chroma Medicine enter option and license agreement leveraging ZFPs - Sangamo and Chroma Medicine announced they have entered into a research evaluation, option and license agreement to develop epigenetic medicines leveraging zinc finger proteins, or ZFPs, for sequence-specific DNA recognition. Over the course of two decades, Sangamo has built and validated the world's largest library of ZFPs, deploying them to address numerous therapeutically relevant targets. Advancing the transformative potential of epigenetic editing, Chroma is expanding the versatility of its platform by leveraging Sangamo's ZFPs. Following a research evaluation period, Chroma has the option to license the ZFPs for potential worldwide development and commercialization of epigenetic medicines for certain therapeutic targets. Under the terms of the agreement, Chroma will evaluate novel Sangamo ZFPs for specified collaboration targets outside of the central nervous system in exchange for an upfront technology access payment. If Chroma exercises its option for any or all targets, Sangamo would be eligible to receive an option exercise payment, in addition to potential development and commercial milestone payments, as well as royalties on any Chroma products incorporating the licensed ZFPs. Chroma will lead and fund all research, development, manufacture, and commercialization of products incorporating the licensed Sangamo ZFPs.
|
OESX | Hot Stocks08:14 EDT Orion Energy commences onsite installation for $9.6M contract for U.S. DoD - Orion Energy Systems announced that it has commenced on-site installation activities for a previously announced $9.6 million contract for LED lighting retrofits at five Department of Defense, DoD, bases in Europe. The turnkey retrofit program includes site audits, engineering, project management, replacement of over 60,000 fixtures with its highly efficient LED lighting systems and final system commissioning. These projects were secured through a global ESCO based in Europe. Following initial activities in Q4'23 and Q1'24, Orion continues to expect to complete the project over the balance of its current fiscal year which ends March 31, 2024. "We are thrilled to leverage our extensive experience working with the U.S. Department of Defense to support their energy efficiency, workplace environment, and safety objectives," stated Mike Jenkins, CEO of Orion. "The start of this turnkey LED installation is a significant milestone we have been working toward for several years. It was made possible through strong relationships with our ESCO partners and marks our first venture in Europe for the DoD. We are delighted to witness the growth of our collaboration with our global ESCO partner and are currently exploring future opportunities across their diverse operation."
|
SNY | Hot Stocks08:13 EDT Sanofi enters strategic collaboration with Recludix Pharma - Recludix Pharma announced that the company has entered into a strategic collaboration with Sanofi to develop and commercialize first-in-class oral small molecule STAT6 inhibitors for patients with immunological and inflammatory diseases. Under the partnership, Sanofi will have global rights to small molecule STAT6 inhibitors. Recludix will advance STAT6 inhibitors from preclinical research and development until the start of Phase 2 clinical trials. Sanofi will assume worldwide clinical development and commercialization responsibilities thereafter. Recludix has the option to participate in U.S. profit/loss share, which includes the ability to share equally in the costs, profits and losses, and to certain co-promotion activities for the partnered product in the U.S. Recludix will receive $125 million in near-term payments, and additionally, Recludix may receive more than $1.2 billion in potential development, regulatory and sales milestones, as well as up to double-digit royalties on possible future product sales.
|
XWEL | Hot Stocks08:11 EDT Xwell debuts Clockwork robotic manicures at Miami International Airport - XWELL launched the use of Clockwork's next generation, fully autonomous, AI-powered express manicure in the XpresSpa location at Miami International Airport (MIA) in Miami, Florida. MIA's North Terminal, Concourse D is the second airport location in the world to feature robot manicures following the debut at John F. Kennedy International Airport's Terminal 4 in March 2023.
|
VIR | Hot Stocks08:11 EDT Vir's PENINSULA trial of VIR-2482 did not meet primary efficacy endpoint - Vir Biotechnology announced that the Phase 2 PENINSULA trial evaluating VIR-2482 for the prevention of symptomatic influenza A illness did not meet primary or secondary efficacy endpoints. In participants who received the highest dose of VIR-2482, a non-statistically significant reduction of approximately 16% in influenza A protocol-defined illness was observed. Participants who received the highest dose showed an approximately 57% reduction in symptomatic influenza A illness, when defined according to CDC influenza-like-illness criteria, which was one of two secondary endpoints. VIR-2482 was generally well tolerated and no safety signals were identified. "We are grateful to all who participated in this trial, and we remain committed to the pursuit of novel therapies that have the potential to address some of the world's most serious infectious diseases," said Marianne De Backer, M.Sc., Ph.D., MBA, Vir's Chief Executive Officer. "I'm very excited about the future ahead, with the opportunities that we have, including a robust pipeline, where we expect two data readouts across our hepatitis B and hepatitis D programs in 2023. We also have a strong balance sheet with approximately $1.9 billion in cash and investments, as of the end of the second quarter, which will allow us to invest in our ongoing development and future innovation."
|
RKDA | Hot Stocks08:11 EDT Arcadia Biosciences announces strategic review - Arcadia Biosciences disclosed that it has initiated a process to explore a range of potential transactions and alternative strategies focused on maximizing long-term shareholder value. As part of this process, the company will explore strategic options that may include the potential for an acquisition, company sale, merger, business combination, asset sale, joint venture, licensing arrangement, capital raise or other strategic transaction. Lake Street Capital Markets will act as Arcadia's financial advisor with respect to the strategic review process. There can be no assurance that this exploration of strategic alternatives will result in the company entering or completing any transaction, and no timetable has been set for the conclusion of the strategic review.
|
ATXS | Hot Stocks08:11 EDT Astria: STAR-0215 gets fast track for treatment of Hereditary Angioedema - Astria Therapeutics announced that the STAR-0215 development program has received Fast Track designation from the U.S. Food and Drug Administration FDA for the treatment of Hereditary Angioedema HAE , a rare genetic disorder that causes severe unpredictable attacks of swelling throughout the body. STAR-0215 is currently being evaluated in the ALPHA-STAR clinical trial in people with HAE, with initial proof-of-concept results expected in mid-2024. "Receiving Fast Track designation for STAR-0215 is an important milestone that underscores the need for HAE therapies that can normalize the lives of people living with HAE with dosing every three or six months," said Jill C. Milne, Ph.D., Chief Executive Officer at Astria Therapeutics. "We look forward to more frequent communication with the FDA as we work to reduce both the disease and treatment burden for the HAE community." The FDA Fast Track process is designed to expedite the development and review of therapies to treat serious or life-threatening conditions and that demonstrate the potential to address unmet needs. Companies that receive Fast Track designation for a product candidate are able to submit New Drug Applications (NDA) for such candidate on a rolling basis, potentially expediting the FDA review process, and benefit from more frequent communication with the FDA to discuss all aspects of clinical development. In addition, drugs that receive Fast Track designation may be eligible for a priority review if certain criteria are met.
|
VRSSF | Hot Stocks08:10 EDT Verses AI presents novel theories at ASSC - VERSES AI announces presentation of its developments and contributions at the Association for the Scientific Study of Consciousness. The 26th annual meeting of the Association for the Scientific Study of Consciousness, held at New York University, last month, welcomed a variety of distinguished keynote speakers, presenters and philosophers including Thomas Nagel, David Chalmers and two contributors from VERSES -Director of Product, Mahault Albarracin, and Senior Researcher, Alex Kiefer, who presented novel and potentially disruptive theories in cognitive neuroscience. Albarracin presented findings on a model of consciousness derived from the free-energy principle. After outlining the classical and quantum formulations of FEP, Albarracin discussed its implications on the sparse, nested and hierarchical neuro-anatomy of the brain. The highlight of Albarracin's presentation was the examination of the holographic structure of the brain and how it supports overt and covert action. The research connects our understanding of human consciousness with AI development, fostering a novel approach to AI at VERSES. Kiefer, stationed at Monash University, challenged traditional cognitive science debates, asserting that 21st-century advancements in the theory of cognitive systems, particularly those linked with sophisticated AI and machine learning, have rendered two "outdated" dichotomies. The first dichotomy Kiefer dismantled was between iconic and discursive representations or representational formats. The second, was between formal, rule-governed processes or state transitions and associative ones. Kiefer's talk elucidated the role and function of vector space embeddings - common elements in all successful deep learning systems - as being more flexible and capable than traditionally recognized. He presented four key theses highlighting the capabilities of vector space representations and their roles in modern paradigms in cognitive science. Kiefer's research aims to broaden our understanding of AI, offering insights into the workings of advanced systems.
|
TOPS | Hot Stocks08:10 EDT TOP Ships announces time charger agreement with Clearlake Shipping - TOP Ships announced that it has agreed to extend for up to 36 months the time charter agreements with Clearlake Shipping Pte for its two Suezmax vessels, M/T Eco West Coast and M/T Eco Malibu. The extended period, which starts after the expiration of the present time charters in Q1 of 2024, has a firm duration of a minimum of 30 months and a maximum of 36 months at a gross daily rate of $32,850. All other main terms of the contracts that had been previously announced, including the charterer's option to extend the charters for 2 additional years at a gross daily rate of $34,750 for the first year and $36,750 for the second year, remain unchanged. The additional revenue backlog expected to be generated by this time charter extension is about $72 million for the maximum firm period. Evangelos Pistiolis, the President, Chief Executive Officer and Director of the Company, said: "We are very pleased to have concluded this time charter extension more than half a year ahead of the firm period expiration of the present employment of our 2 vessels, taking advantage of the strong rates prevailing in the current tanker market. This is an attestation, from a top-class charterer, of the high level of quality of our vessels as well as the services that we offer. After considering the maximum firm duration of this fixture, the total gross revenue backlog as of December 31, 2022 for the firm time charter period of our operating vessels, including 50% of our joint venture vessels, that was previously announced at $280 million is increased to about $352 million."
|
TKNO | Hot Stocks08:08 EDT Alpha Teknova, Sartorius BIA Separations share data on AEX platform - Alpha Teknova and Sartorius BIA Separations shared new data that demonstrates the ability to improve the recovery of full AAV capsids during anion-exchange, AEX, purification, which will help gene therapy companies streamline the downstream processing workflow. Teknova presented the findings from the companies' first collaboration earlier this week during a presentation entitled, "Enhancing AAV Full Capsid Enrichment with an Optimized AEX Platform: A Case Study." After identifying capsid enrichment as a critical pain point in the AAV gene therapy workflow, Teknova and Sartorius BIA Separations began working together to address the challenges gene therapy developers face. By using a robust design of experiments approach, the companies were able to achieve more than 85 percent full capsid enrichment with 80-95 percent recoveries using custom Teknova buffers along with the Sartorius BIA Separations CIMmultus QA monolith for the polishing step, given a specific starting material of AAV8 that contained 46 percent full capsids. The buffers and parameters discovered in this study were then further optimized to create a first-of-its-kind product available off-the-shelf for gene therapy developers: Teknova's AAV-Tek AEX Buffer Screening Kit for AAV8.
|
RNXT | Hot Stocks08:07 EDT RenovoRx, Imugene announce oncolytic virus therapy collaboration, using TAMP - RenovoRx and Imugene announced a strategic research collaboration to optimize the delivery of Imugene's oncolytic virus therapy with RenovoRx's TAMP or Trans-Arterial Micro-Perfusion, therapy platform for the treatment of difficult-to-access tumors. "We believe the synergy between RenovoRx's trans-arterial drug delivery system and our CF33 oncolytic virus platform has the potential to facilitate treatment of difficult-to-access cancers and help patients," said Leslie Chong, Managing Director & Chief Executive Officer of Imugene. "Our collaboration with Imugene is an important milestone for RenovoRx as we expand our pipeline from exclusively treating locally advanced disease to treating metastatic disease with immunotherapy," said Shaun Bagai, Chief Executive Officer, RenovoRx. "We look forward to combining our proprietary TAMP platform with Imugene's CF33 oncolytic virus with the goal of optimizing clinical benefits for patients." As part of the collaboration, Imugene and RenovoRx will investigate the ability to administer Imugene's CF33 oncolytic virus technology with RenovoRx's TAMP therapy platform. The ability to treat difficult-to-access tumours, such as pancreatic and liver cancers, by delivering CF33 trans-arterially may be valuable to cancer patients compared to traditional administration methods where dense fibrous tissue and lack of blood vessels supplying the tumours have been shown to limit therapy uptake.
|
HRMY | Hot Stocks08:07 EDT Harmony completes End-of-Phase 2 meeting with FDA for pitolisant - Harmony Biosciences Holdings has successfully completed an End-of-Phase 2 meeting with FDA regarding its clinical development plan evaluating pitolisant as a potential treatment for excessive daytime sleepiness, or EDS, in patients ages six and older with Prader-Willi syndrome, or PWS. Harmony plans to initiate a Phase 3 registrational study in the Q4. Based on a positive signal observed from the Phase 2 proof-of-concept study, Harmony aligned with the FDA on the proposed Phase 3 study design elements to support further investigation of pitolisant for children, adolescents and adults with PWS experiencing EDS. There is currently no FDA-approved treatment for EDS in this patient population.
|
AMRN | Hot Stocks08:07 EDT Amarin announces executive compensation program for new president, CEO - The Board of Directors of Amarin Corporation announced details regarding the compensation program for the Company's new President and CEO, Patrick Holt, who was appointed to the role on July 18, 2023. Under the terms of the agreement, the vast majority of Mr. Holt's total target compensation is tied to the creation of shareholder value, in the form of options to be granted shortly after his joining the Company. The realizable value is at-risk equity and directly dependent upon the sustained performance of the Company's share price and, thus, aligned with the interest of shareholders. A summary of the material terms of Mr. Holt's equity incentive award is as follows: Mr. Holt will be issued a one-time grant of stock options giving him the right to purchase up to 5,000,000 shares subject to performance-based vesting with share price hurdles ranging from $2.50 to $15.00. Upon achievement of each share price hurdle, a set number of shares are earned. For each share price hurdle to be achieved, the volume weighted average price of the shares over a 60-day calendar period must equal or exceed the applicable share price hurdle. Once a share price hurdle has been achieved, the earned option shares are subject to an additional five months of time-based vesting to further support sustained stock price appreciation. Mr. Holt has also agreed to purchase $300,000 worth of Amarin shares in the open market using personal funds. Additional details regarding Mr. Holt's executive compensation are included in his employment agreement with the Company, which will be subsequently filed with the U.S. Securities and Exchange Commission.
|
MOTS | Hot Stocks08:07 EDT Motus GI announces purchase agreement for Pure-Vu System from Banner Desert - Motus GI announced that Banner Desert Medical Center has purchased and initiated the implementation of the Pure-Vu System with the aim of improving efficiencies and clinical outcomes of inpatient colonoscopy procedures for patients who present with inadequate bowel preparation. Banner Desert Medical Center is a state-of-the-art 615-bed short-term acute care hospital located in Mesa, Arizona. "We are excited to engage the GI team at Banner Desert Medical Center as they implement the Pure-Vu System. As the first center in the Banner Medical network to purchase our system, we look forward to leveraging the success of their program to expand into additional medical centers within Banner's broad network across several western states, including Arizona, Colorado, and Wyoming," stated Mark Pomeranz, Chief Executive Officer of Motus GI. "Over the past year, our commercial team has successfully expanded the number of placements of the Pure-Vu system within several large regional, multi-center integrated delivery networks across the U.S."
|
CASI | Hot Stocks08:06 EDT Casi obtains all rights related to CB-5339 novel VCP/p97 inhibitor - CASI Pharmaceuticals announced the execution of the Assignment Agreement with Cleave Therapeutics, pursuant to which CASI obtained all rights and global intellectual property rights related to CB-5339, a novel VCP/p97 inhibitor, as well as all remaining CB-5339 drug substance and drug product. Additionally, CASI will assume responsibility of the US CB-5339 Investigational New Drug, or IND, application. CB-5339 is an oral, second-generation, small molecule valosin-containing protein, or VCP, /p97 inhibitor, designed to disrupt protein homeostasis, DNA damage response and other cellular stress pathways. In a Phase 1 clinical trial in patients with acute myeloid leukemia and myelodysplastic syndrome, the drug was well tolerated in 55 patients and demonstrated signs of clinical activity. Two patients remain on CB-5339 under compassionate use protocols at two leading US cancer centers.
|
LGVN OTSKY | Hot Stocks08:05 EDT Longeveron appoints Locklear as Chief Financial Officer - Longeveron (LGVN) announced the appointment of Lisa Locklear as Executive Vice President and Chief Financial Officer. The appointment is effective as of July 31, 2023. Locklear joins Longeveron from Avanir Pharmaceuticals, a subsidiary of Otsuka (OTSKY), where she served as Senior Vice President and CFO.
|
LOW WOOF | Hot Stocks08:05 EDT Lowe's, Petco expand pilot program - Lowe's (LOW) and Petco Health + Wellness Company (WOOF) announced the expansion of their pilot program that brings trusted products, services and expertise - for both home and pets - into a one-stop shop, growing from 15 Lowe's stores to nearly 300 locations by year-end. Focusing on rural communities across the country, this expansion offers a new convenience to shoppers, providing access to pet supplies and veterinary care along with everything DIY and Pro customers need for their home improvement projects.
|
GRRR | Hot Stocks08:05 EDT Gorilla enters strategic relationship with British Telecom - Gorilla Technology Group announced a strategic relationship with British Telecom to deliver an innovative Container Identification and Container Damage Detection solution. This groundbreaking collaboration, which is being actively deployed and tested at the Port of Tyne in Northern England, combines Gorilla's expertise in video analytics with BT's extensive network infrastructure, enabling a comprehensive solution that addresses the critical needs of the logistics industry. With the global container shipping industry experiencing unprecedented growth, it has become increasingly challenging for stakeholders to efficiently manage container identification and detect potential damages. Traditional manual inspection methods are time-consuming and prone to human error, leading to significant operational inefficiencies and financial losses. To tackle this industry-wide challenge, Gorilla and BT have joined forces to develop an intelligent, automated solution that leverages advanced video analytics technologies. The container identification and container damage detection solution developed by Gorilla harnesses the power of Artificial Intelligence and machine learning algorithms to analyze video footage captured at various stages of the container management process. By leveraging BT's robust network infrastructure and Gorilla's state of the art video analytics platform, the solution can accurately and rapidly identify containers, track movements, and detect any signs of damage or tampering. The solution is currently being deployed at the Port of Tyne.
|
ACRV ZNTL | Hot Stocks08:04 EDT Acrivon appoints Levy as SVP, head, investor relations and corporate affairs - Acrivon Therapeutics (ACRV) announced that Adam D. Levy, Ph.D., M.B.A., has joined Acrivon as senior vice president, SVP, and head, investor relations and corporate affairs. Previously, Adam served as senior vice president of investor relations at Zentalis Pharmaceuticals (ZNTL).
|
REPL | Hot Stocks08:04 EDT Replimune Group director Sander Slootweg to depart - Replimune Group announced Sander Slootweg, founder and managing partner at Forbion, will not seek to be reappointed as a non-executive director at the end of his current term at the company's upcoming annual general meeting.
|
HILS OABI | Hot Stocks08:03 EDT Hillstream BioPharma expands collaboration with Minotaur, OmniAb - Hillstream BioPharma (HILS) announced the expansion of its collaboration with Minotaur Therapeutics and its license agreement with OmniAb (OABI) to advance the development of next generation targeted Knob biologics against HER3 and a new undisclosed oncology target. Hillstream will collaborate with Minotaur using OmniAb's "OmniTaur" technology to discover targeted biotherapeutic Picobodies complementing Hillstream's most advanced program, HSB-3215, a HER2/HER3 bispecific antibody. Randy Milby, Chief Executive Officer of Hillstream, stated, "We are extremely pleased with the progress made to date. The Knob biologics program continues to be a great addition to our portfolio as we rapidly progress our lead asset HSB-3215 towards an IND. Hillstream is now poised to develop a novel technology for creating multiple proteins to enhance targeted cancer immunotherapy."
|
ENPH | Hot Stocks08:03 EDT Enphase Energy, BayWa r.e. expand distribution partnership - Enphase Energy announced that Enphase has expanded its global relationship with renewable energy company BayWa r.e. to distribute Enphase's family of IQ8 Microinverters in Poland, including the latest models with peak output AC power of up to 384 W to support newer high-powered solar modules.
|
WKSP | Hot Stocks08:02 EDT Worksport achieves milestone with first assembly line completion - Worksport announces an eagerly awaited update on its operational developments. With its first assembly line now completed and primed for action, the Company is on track to start production in just three weeks. This feat paves the way for the eventual completion of a total of five assembly lines. With each successive line, the Company is poised to increase its capacity, reinforcing its market position and readiness to meet escalating demand. CEO Steven Rossi reflects on this pivotal moment, stating, "It took us some time to set up the initial assembly line, but moving forward, we anticipate subsequent lines to be ready more quickly. This accomplishment is a testament to our team's dedication and the solid groundwork laid in our West Seneca, New York facility."
|
THG | Hot Stocks07:52 EDT The Hanover sees Q2 catastrophe losses $262M - The Hanover Insurance Group announced a preliminary estimate for Q2 quarter catastrophe losses of approximately $262M, before taxes, or 18.5 points of net earned premium. Q2 catastrophe losses stemmed from 19 convective storms across multiple states, with hail damage representing the majority of reported losses and primarily impacting the company's Personal Lines business. "We experienced significant catastrophe losses in the second quarter, which according to industry estimates, is expected to be the worst Q2 for U.S. catastrophe losses since 2011, and potentially the industry's costliest quarter for hail losses in history," said John C. Roche, president and CEO. "Our CAT losses reflect the impact of severe weather, notably the prevalence and severity of hailstorms in Michigan, where we have our largest Personal Lines presence. Excluding catastrophes, our second quarter results are in line with our expectations, due to solid net investment income and strong results in our Specialty and Core Commercial businesses, partially offset by the continuing impact of inflationary trends in Personal Lines." Taking catastrophe loss estimates and other currently available information into account, The Hanover expects to report a Q2 combined ratio of 111.3%, and combined ratio, excluding catastrophes, of 92.8%. The Hanover also expects to report an after-tax net loss per basic share of ($1.94) and operating loss per basic share of $(1.91) for the Q2.
|
TLLTF | Hot Stocks07:46 EDT Tilt Holdings announces grand opening of New Dia at Fenway location - TILT Holdings announced on behalf of New Dia Cannabis that New Dia will be hosting a grand opening on Saturday, July 22, 2023, to celebrate its new brick and mortar store located at 71 Lansdowne St, Boston, MA, directly across from Gate E at Fenway Park. The event kicks off at 2:00 p.m. EST with a ribbon-cutting ceremony at 3:00 p.m. EST. The festivities include a Mario Kart tournament on a 14-foot LED screen sponsored by LC Square, custom on-site t-shirt printing from Greencare Collective, an appearance by 98.5 The Sports Hub, opportunities to win tickets to neighborhood concerts and ball games, swag giveaways, music, food and more.
|
WBS | Hot Stocks07:44 EDT Webster Financial sees Fy23 loan growth 4%-6%, core deposit growth 8%-10% - Sees FY23 NII $2.35B-$2.375B non-FTE, excluding accretion. Sees FY23 non-interest income $355M-$365M, with adjusted expenses $1.2B-$1.225B and an efficiency ratio 40%-42%. The firm's long-term CET1 capital ratio target is 10.5%. Comments taken from Q2 earnings conference call presentation slides.
|
AGEN | Hot Stocks07:40 EDT Agenus names Robin Taylor, Homa Yeganegi, Stephanie Fagan to executive team - Agenus announced the appointment of Robin Taylor, Ph.D., Homa Yeganegi and Stephanie Fagan to its executive team. The newly appointed leaders bring a wealth of industry experience to drive the company's next phase of growth in the development and planned commercialization of botensilimab and a deep pipeline of immuno-oncology programs, which offer potential breakthroughs in cancer therapeutics. Chief Commercial Officer, Robin Taylor, Ph.D., is an accomplished leader with demonstrated success in global commercial development in oncology. His expertise in commercialization strategies, market access, and product launches will accelerate Agenus' growth and ultimately enable the delivery of the company's therapies to patients as the company evolves to a multi-product organization. Chief Product Strategy and Global Medical Affairs Officer, Homa Yeganegi, brings expertise in medical affairs and a passion for advancing patient care. Her success in building and leading global medical affairs teams will play a pivotal role in deepening physicians' understanding of the transformational potential of botensilimab. By fostering strong relationships with the medical community, she will contribute to the development and future commercialization of the company's immuno-oncology programs.
|
KELYA | Hot Stocks07:39 EDT Kelly Services announces workforce reduction and strategic restructuring plan - Kelly announced strategic restructuring actions that will further optimize the company's operating model to enhance organizational efficiency and effectiveness. These actions are part of the comprehensive transformation initiative the company announced in May to drive EBITDA margin improvement and accelerate long-term profitable growth. The strategic restructuring actions realign business-critical resources to Kelly's business units, streamline corporate resources, reduce redundant organizational layers, and optimize work processes. These structural changes simplify the company's operations and unlock additional resources to invest in growth. As a result of these actions, the company has implemented a workforce reduction plan and notified affected employees in accordance with applicable employment laws and regulations. Employees whose roles were included in the workforce reduction are eligible for applicable severance, benefits, and outplacement services. As a result of the strategic restructuring actions, Kelly expects to see meaningful expansion of its EBITDA margin beginning immediately with substantial improvement in the second half of 2023 and beyond. The company expects to incur a restructuring charge from these actions in the range of $7.5M-$8.5M in the Q3. Peter Quigley, CEO, and Olivier Thirot, executive vice president and CFO will provide additional details about the strategic restructuring as it relates to the company's ongoing transformation, including expectations for EBITDA margin improvement, during its upcoming Q2 conference call.
|
ABT | Hot Stocks07:38 EDT Abbott reports Q2 worldwide Medical Devices sales up 13.5% on reported basis - Worldwide Medical Devices sales increased 13.5% on a reported basis and 14.2% on an organic basis in the second quarter. Sales growth was led by double-digit organic growth in Diabetes Care, Electrophysiology, Structural Heart and Neuromodulation. Several recently launched products and new indications contributed to the strong performance, including Amplatzer Amulet, Navitor, TriClip, and Aveir. In Electrophysiology, internationally, sales grew high-teens on a reported basis and more than 20% on an organic basis, which includes high-teens growth in Europe. In Diabetes Care, FreeStyle Libre sales were $1.3B, which represents sales growth of 22.9% on a reported basis and 24.7% on an organic basis.
|
ARWYF NEXCF | Hot Stocks07:34 EDT ARway.ai secures $500,000 annual license agreement with Map D - ARway.ai (ARWYF) announced a partnership with Map D, an event technology company wholly owned by Nextech3D.ai (NEXCF). This strategic collaboration aims to disrupt the lucrative trade show industry through the introduction of ARway's cutting-edge augmented reality indoor navigation system. Under the terms of the license agreement, ARway will receive monthly payments totaling $41,666 for a duration of 12 months, amounting to a minimum guarantee of $500,000. Furthermore, should sales exceed $500,000 within any 12-month period, ARway will be entitled to a 10% royalty. Throughout the term, ARway will deliver comprehensive customer support and technical assistance to ensure a seamless integration and optimal experience for all stakeholders.
|
VRNOF | Hot Stocks07:31 EDT Verano Holdings appoints Tipton, Mueller to board of directors - Verano Holdings announced the appointment of John Tipton, President of the Southern Region, and Charles Mueller to its Board of Directors in conjunction with the retirement of Mike Smullen. Following Mike Smullen's resignation from the Board on July 19, 2023, the Board approved a proposal to increase in size from four to five members, with Tipton and Mueller filling the two vacancies. Tipton served as President of the Company from February 2021 until June 2023, when he was named President of the Southern Region. Since 2021, Mueller has provided independent corporate tax consulting services to Tropicana Products, Inc. and Cresa Partners Boston.
|
ZTEK | Hot Stocks07:22 EDT Zentek, McMaster announce results for aptamer-based technology - Zentek announcedthat its aptamer platform under global exclusive license from McMaster University has been tested as a potential prophylactic or therapeutic for SARS-CoV-2 in pre-clinical animal models. In repeat trials, the aptamers developed by Dr. Yingfu Li demonstrated similar efficacy against SARS-CoV-2 when benchmarked against a commercial monoclonal antibody. This new aptamer, based on a novel approach, was developed under the exclusive worldwide 20-year license agreement between Dr. Li's lab at McMaster and Zentek first announced on June 17, 2021. Dr. Yingfu Li's team developed a series of aptamers with high-binding affinity with the SARS-CoV-2 spike protein. In February 2023, the best performing aptamer against all variants of SARS-CoV-2 was tested in vitro to assess the neutralizing of the virus by the aptamer in Vero cells. With strong results, Zentek was motivated to move into in vivo trials. Dr. Matthew Miller, the Canada Research Chair in Viral Pandemics and the director of the Michael G. DeGroote Institute of Infectious Disease Research designed and supervised all of the pre-clinical trials. The first pre-clinical trial included three groups of mice: Group A, which was a control group and received no prophylactic treatment, Group B, which received a commercial monoclonal antibody that was a leading antibody for the original SARS-CoV-2 strain until it was rendered ineffective due to antigenic changes in Omicron sublineages,and Group C, which received an aptamer designed by Dr. Li's team. All groups were infected with SARS-CoV-2. After four days, the mice that received the antibody and aptamer treatment had minimal weight loss, while the control group had a 10% body weight decline. In addition, the viral burden of the control group was measured at 10,000 PFU per lung. Significantly, the viral burden was undetectable in the lungs of the mice treated with the antibodies or the aptamer. Based on these results, an additional trial was completed following the same procedure with a lethal challenge dose of SARS-CoV-2 where the mice were once again divided into three groups: control, antibody, and aptamer treatment. The control or untreated group lost 20% of their body weight after four days and all mice reached humane endpoints. The groups receiving either the aptamer or antibody treatment had less than a 5% reduction in bodyweight after the four days. The gross pathological assessment of these lungs at day 4 post-infection indicated that the aptamer, like the antibody, completely protected the lungs from any observable tissue damage. The control group's lungs on the other hand had evidence of significant hemorrhaging. In addition, the antibody and aptamer prophylactic provided sterilizing protection where no detectible viral titers were measurable, demonstrating similar performance between the commercial monoclonal antibody and the Li Lab aptamer. Aptamers are synthetic single stranded DNA or RNA type molecules that are built from the same building blocks of human DNA or RNA; hence offering a significant positive safety profile and have already demonstrated such safety. The 2018 article entitled "Pharmacokinetics, Pharmacodynamics, and Safety of Aptamers" by Kovacevic et al. stated that aptamers are considered to be generally safe based on multiple studies of aptamers for therapeutic use. Reference to toxicology studies and off-target side effects also lead to the concluding statement that generally, the safety of aptamers is very good. Given the significance of these results and based on the importance of this opportunity, a pre-clinical plan is being formulated for the development of a COVID-19 therapeutic/prophylactic based on the Dr. Li aptamers. Dr. Li is also working on other targets for aptamer treatments, and these are under early investigation.
|
TLRY WFC | Hot Stocks07:19 EDT Tilray's SweetWater Brewing presents ATLive concert series - SweetWater Brewing Company, subsidiary of Tilray Brands (TLRY), announced last week its partnership with AMB Sports and Entertainment, AMBSE, to bring the biggest music artists to Mercedes-Benz Stadium with the return of the highly anticipated ATLive concert series powered by Ticketmaster and presented by SweetWater Brewing and Wells Fargo (WFC). The two-day music event returns on Friday, October 20, and Saturday, October 21. Friday's lineup will feature energetic performances, led by Latin GRAMMY Award-winners Grupo Firme, along with J Balvin, GRAMMY-nominated rapper and singer/songwriter Farruko, and Latin GRAMMY-nominated sibling trio Yahritza Y Su Ensencia. Saturday feature country icon George Strait, Carrie Underwood, Willie Nelson & Family, and Little Big Town. "This will be one of Atlanta's biggest weekends for Latin and Country music, and SweetWater Brewing will be there to help fans enjoy the show with its refreshing beers and canned cocktails," said Ty Gilmore, President, U.S. Beers for Tilray. "Our partnership with AMB Sports and Entertainment is yet another way that we're connecting with the Atlanta community in new, exciting ways."
|
WHGOF... | Hot Stocks07:17 EDT White Gold commences maiden RAB drill program on Wolf, Toonie properties - White Gold Corp. (WHGOF) provides an update on regional components of the 2023 exploration program (Figure 1) which are designed to test several of White Gold's most prospective, yet relatively untested soil geochemical targets which are sizeable enough geochemical footprints that, if successful, could be capable of hosting significant deposits. As part of this regional program, the Company designed a maiden Rotary Air Blast drilling on the Wolf and Toonie properties to test large soil geochemistry anomalies on both properties, identified through the Company's systematic exploration approach that has led to several other discoveries on its other properties. Maiden RAB drilling has commenced on the Wolf Property on the Taurus target, a large approximately 2 km long by 0.5 km wide, northeast-trending gold in soil anomaly, with maximum values of 358 ppb Au and multiple anomalous GT probe sampling results. On the Toonie Property, maiden RAB drilling is currently underway on the Deux target located in the northwestern region of the property and forms a 1.5 km by 0.5 km east-west trending multi-element soil anomaly, including maximum values of 156 ppb Au. This work forms part of the Company's fully funded 2023 exploration program backed by strategic partners Agnico Eagle Mines (AEM) and Kinross Gold Corporation (KGC). The Company's land package represents over 40% of the emerging White Gold District in Yukon, Canada in which the Company has made several high grade gold discoveries such as Betty Ford, Ryan's Surprise & Vertigo, and has significantly increased resources at the Company's flagship White Gold Project which now comprises 16 million tonnes averaging 2.23 g/t Au for 1,152,900 ounces of gold in the Indicated Resource category and 19 million tonnes averaging 1.54 g/t Au for 942,400 ounces of gold in the Inferred Resource category and remains open for expansion. Highlights: Maiden RAB drilling of 300 m at the Wolf property on the Taurus target, where the four RAB holes were designed to test a large 2 km long by 0.5 km wide gold in soil anomaly, with maximum values of 358 ppb Au, along strike and the dip of the zone at depth. Maiden RAB drilling of 300m at the Toonie property on the Deux target, which hosts a 1.5 km by 0.5 km multi-element soil anomaly including maximum values of 156 ppb Au, with holes placed to test the full 1.5 km strike length of the anomaly. All RAB holes are imaged with downhole optical televiewer, which provides optical records of the borehole wall, to allow for real-time detailed structural analysis and interpretation as drilling progresses. RAB drilling at both the Wolf and Toonie properties have been awarded Yukon Mineral Exploration Program grants for Target Evaluation. Results on the Company's 2023 exploration program, including the recently completed diamond drilling at the Betty Ford and Vertigo targets will be announced in due course. Maiden diamond drilling on the Cali Target located on the Nolan property will test a 2km long gold and multi-element soil anomaly is set to commence in coming weeks, with further details announced in due course. Other components of the regional exploration program include Induced Polarization - Resistivity ground geophysical surveys over the large Copper-Molybdenum porphyry targets located on the Pedlar and Hayes properties, and additional work to generate new targets for future drill testing including geological mapping and prosecting, soil geochemistry surveys, and ground magnetics and VLF-EM surveys with additional detail to be provided in the coming weeks.
|
OSIIF | Hot Stocks07:16 EDT Osino Resources announces assay, metallurgical results from Ondundu project - Osino Resources provides an update on the recently completed infill and orientation drill program at the Ondundu Gold Project. Dave Underwood, Osino's VP Exploration commented: "The short drill program we recently completed at Ondundu has produced some exceptional intercepts including 157m @ 1.50g/t in hole ONRC23-019 and 109m @ 2.30g/t as previously reported in hole ONRC23-017. These results indicate potential to increase the size and grade of the main ore zones with further detailed infill and step-out drilling. In addition, the two holes drilled in a westerly orientation to check for mineralization perpendicular to the main ore shoots, intersected unexpected mineralization to the east of the current resource and indicate potential to define a new zone of mineralization in an area never previously drilled."
|
ZFOX | Hot Stocks07:15 EDT ZeroFox contributes to open source OWASP Amass Project - ZeroFox highlights its recent contributions to the OWASP Amass Project in an ongoing effort to give businesses and government entities better visibility to their full external attack surface asset ecosystem. The recent additions to the project from the ZeroFox team provide more advanced tool sets for analysts to discover and catalog their internet-facing assets and exposures. The contributions create a new standard framework to lead the industry in a more cohesive approach to attack surface management. The Open Asset Model and Asset Database contributions offer security analysts a unified and structured approach to identifying and managing potential vulnerabilities outside the perimeter. The Open Asset Model provides a new standard for asset definitions, representing a comprehensive framework for describing and categorizing diverse internet-facing assets. The Amass community can quickly adapt the model to include new types of assets exposed on the Internet, and their relationships to each other, for more accurate discovery, tracking, monitoring, and management. These contributions directly benefit both existing Amass users and the broader attack surface management community in an effort to standardize asset definitions. The new standards now provide the information security community with a consistent and predictable format when transferring data describing external attack surfaces.
|
EU | Hot Stocks07:14 EDT Anfield completes acquisition of Neutron Energy - Anfield Energy announce, further to its news release of June 6, that it has completed the acquisition of Neutron Energy, a wholly-owned subsidiary of enCore Energy, which holds the Marquez-Juan Tafoya uranium project located in the Grants Uranium Mineral District, 50 miles west-northwest of Albuquerque, New Mexico. As consideration for the acquisition of Neutron, the Company has issued 185,000,000 common shares to enCore and has agreed to pay C$5,000,000 in cash. Pursuant to an agreement reached with enCore, C$4,000,000 of the Consideration Payment was made at closing, with the balance due and owing on or before September 25, 2023. The Company has also granted enCore the right to nominate one director to the board of the Company, to serve so long as enCore continues to hold at least 10% of the outstanding shares of the Company. During this time, enCore has agreed to vote the Consideration Shares in support of any decisions made by management of the Company. Eugene Spiering has been appointed to the board of directors of the Company as the initial nominee of enCore. The Company is at arms-length from enCore and Neutron. The Consideration Shares are subject to statutory restrictions on resale until November 20, 2023 in accordance with applicable securities laws. No finders' fees or commissions are owing by the Company in connection with the Transaction.
|
OSUR A | Hot Stocks07:14 EDT OraSure elects McMahon to its board of directors - OraSure Technologies (OSUR) announced the election of Robert McMahon, CMA, MBA, to the Company's Board of Directors, effective July 31, 2023. Including McMahon, the company's Board of Directors has seven members. McMahon is Senior Vice President and Chief Financial Officer for Agilent Technologies (A) where he is responsible for Finance, Audit, Treasury, Tax, and Investor Relations.
|
BSGM NVDA | Hot Stocks07:13 EDT BioSig Technologies' BioSig AI Sciences selected for NVIDIA Inception program - BioSig Technologies (BSGM) announced that its subsidiary BioSig AI Sciences was selected to join NVIDIA Inception (NVDA), a program designed to partner with companies revolutionizing industries with advancements in artificial intelligence and data sciences. "We are thrilled to join an elite group of AI-centric technology companies leading the evolution of machine learning and AI across industries," said Ken Londoner, Chairman, CEO and Founder of BioSig. "We believe NVIDIA Inception will help advance BioSig's role in identifying transformational applications of AI opportunities in healthcare."
|
KEY | Hot Stocks07:12 EDT KeyCorp sees Q4 NII flat to down 2% vs. Q3 - Sees noninterest income up 4%-6% vs. Q3, with average loans down 1%-3% and relatively stable noninterest expense. The bank sees a GAAP tax rate of 18%-19% in Q4.
|
LTHCF | Hot Stocks07:11 EDT Lithium Ionic reports assay results from Bandeira property - Lithium Ionic reports assay results from its 100%-owned Bandeira property, located within the lithium-rich Aracuai district in the state of Minas Gerais, Brazil. These results form part of an ongoing 50,000 metre expansion and definition drilling program for H2 2023 targeting the Bandeira and Outro Lado lithium deposits, as well as other prospective regional targets, including Salinas and Itira. Bandeira Drill Intercept Highlights 1.89% Li2O over 10.2m; 1.92% Li2O over 6.4m and 1.83% Li2O over 5.9m; 2.10% Li2O over 5.2m; Blake Hylands, P.Geo., Chief Executive Officer of Lithium Ionic, commented, "Our infill drilling program continues to intersect excellent grades and widths, and is delivering on the objective of providing a higher confidence resource to support forthcoming project development studies. We continue to drill with 8 rigs at this target, with another 5 targeting Salinas and Itira."
|
CLSD | Hot Stocks07:11 EDT Clearside's Suprachoroidal Injection platform to be featured at ASRS, OIS - Clearside Biomedical announced today that presentations will be delivered at the American Society of Retina Specialists, ASRS, 41st Annual Scientific Meeting and the Ophthalmology Innovation Source, OIS, Retina Innovation Summit taking place July 27 - August 1, 2023 in Seattle, WA.
|
KEY | Hot Stocks07:11 EDT KeyCorp sees Q3 NII down 4%-6% vs. Q2 - Sees Q3 noninterest income up 2%-4% vs. Q3, with relatively stable noninterest expense and net charge-offs 20-25bps. The company sees a GAAP tax rate of 18%-19%, with average loans down 1%-3%.
|
GILT | Hot Stocks07:10 EDT Gilat Satellite selected by Tier 1 global telecommunications operator - Gilat Satellite Networks announced that a Tier 1 global telecommunications operator chose Gilat for the satellite connectivity of a major utility company in Western Europe. The global telecommunications operator is using Gilat's SkyEdge II-c platform to provide mission-critical, all-weather IoT telemetry across hundreds of remote sites on its utility customer's national network. "Now that this solution is implemented, the leading telecommunications operator will be able to use our platform for expansion into other applications, such as cellular backhaul and emergency response, as well as other types of IoT applications," said Yossi Gal, Vice President of Regional Sales at Gilat. "With proven expertise, a can-do attitude, and a winning global team, we are bringing real value to this important global customer."
|
KEY | Hot Stocks07:10 EDT KeyCorp reiterates long-term targets - In the long term the company expects: positive operating leverage, cash efficiency ratio of 54%-56%, net charge-offs to average loans 40-60 basis points and ROTCE 16%-19%. Guidance taken from Q2 investor presentation slides.
|
NEM | Hot Stocks07:09 EDT Newmont says outlook reflects increasing gold production - The company said, "Newmont's outlook reflects increasing gold production and ongoing investment into its operating assets and most promising growth prospects. Newmont's reserves and mine planning gold price assumption has been set at $1,400 per ounce. 2023 outlook assumes a $1,700 per ounce revenue gold price for CAS and AISC, including royalties and production taxes. For 2023, Newmont has assumed normalizing levels of inflation, improving throughout the year, with a year-over-year average escalation rate of approximately 3 percent. Outlook includes development capital, costs and production related to Tanami Expansion 2, Ahafo North, Pamour and Cerro Negro District Expansion 1. Longer-term development capital outlook has been updated to reflect the deferral of the investment decision for the Yanacocha Sulfides project, which has reduced expected capital spend by $300 million in 2024. Additional development capital spend and all metal production for Yanacocha Sulfides has been excluded from longer-term outlook until an investment decision has been reached."
|
TRVN | Hot Stocks07:09 EDT Trevena appoints Corrigan to its board of directors - Trevena announced that Mark Corrigan, M.D. has been appointed to the Company's Board of Directors, effective July 18 2023. Dr. Corrigan has served as Chief Executive Officer of Tremeau Pharmaceuticals, a pharmaceutical company that Dr. Corrigan co-founded, since January 2023.
|
PM | Hot Stocks07:09 EDT Philip Morris sees strong 2H23 organic adjusted operating income growth - Sees strong second-half 2023 organic adjusted operating income growth that supports second-half adjusted operating income margin expansion on the same basis, with notably strong performance in the fourth quarter.
|
AKTS | Hot Stocks07:08 EDT Akoustis ships two new BAW filters using XBAW foundry process - Akoustis Technologies announced that it has shipped two new Wi-Fi 7 customer designed BAW filters to its tier-2 5G mobile and Wi-Fi access point RF front-end module customer. The two filters were developed using Akoustis' advanced wafer foundry process designed for production in its manufacturing facility in Canandaigua, NY. The filters have been developed for the AP market by the customer using the Akoustis product development kit, to significantly reduce time-to-market for XBAW products and allow the customer to develop proprietary resonators and filters for both broad-based and specific applications. The two new filters were developed by the customer to target the emerging Wi-Fi 7 market with center frequencies at 5.5 GHz and 6.5 GHz.
|
SPPI | Hot Stocks07:07 EDT ISS recommend Spectrum stockholders vote for Assertio transaction - Spectrum Pharmaceuticals (SPPI) announced that the leading independent proxy advisory firms, Institutional Shareholder Services, and Glass Lewis have each recommended that Spectrum stockholders vote "FOR" the proposal to adopt the Agreement and Plan of Merger at the upcoming special meeting of stockholders on July 27. Under the terms of the Merger Agreement, Assertio Holdings (ASRT) would acquire all outstanding shares of Spectrum in an all-stock and contingent value rights transaction. The upfront consideration represents a premium of 65% and the total potential consideration represents a premium of 94% to Spectrum's closing price on April 24.
|
THTX | Hot Stocks07:06 EDT Theratechnologies announces 1-for-4 reverse stock split - Theratechnologies announced that its Board of Directors approved a consolidation of the issued and outstanding common shares of the Company's share capital on the basis of one post- consolidation share for each four pre-consolidation shares issued and outstanding. The Consolidation will be effective July 31, 2023, subject to applicable regulatory approvals, including the Toronto Stock Exchange and the Nasdaq Stock Market. No shareholder approval will be required for the Consolidation to come into effect. The Company expects its common shares will begin trading on the TSX and the NASDAQ on a consolidated basis on or about July 31, 2023.
|
AAL | Hot Stocks07:05 EDT American Airlines continues to execute on plan to pay down $15B of debt - The company said, "American generated operating cash flow and free cash flow of nearly $1.8 billion and $1.2 billion, respectively, in the second quarter. The company reduced total debt4 by $387 million in the quarter. Strengthening the balance sheet continues to be a top priority, and American is nearly two-thirds of the way to its goal of reducing total debt by $15 billion by the end of 2025. As of June 30, 2023, American had reduced its total debt by approximately $9.4 billion from peak levels in mid-2021. The company's commitment to strengthening its balance sheet is being recognized, as evidenced by Fitch upgrading the company's rating two notches, to B+. The company ended the quarter with approximately $14.9 billion of total available liquidity, comprised of cash and short-term investments plus undrawn capacity under revolving and other short-term credit facilities."
|
GFAI | Hot Stocks07:05 EDT Guardforce AI partners with Concorde Security - Guardforce AI announced that it has partnered with leading security provider, Concorde Security, to co-launch a new robotic security solution in Singapore. Guardforce AI's concierge robot will be equipped with an access control module for a visitor management system, a digital system companies employ to register and track each guest entering their facilities. Additionally, Guardforce AI's disinfection robot will be retrofitted and equipped with Concorde's state-of-the-art software security system that will provide automated patrol surveillance. Lei Wang, Chairwoman and Chief Executive Officer of Guardforce AI, stated, "We are excited to partner with Concorde to jointly market robotic solutions that implement the latest AI technology in the security industry. Singapore is a highly interconnected market with stringent security standards, providing the perfect environment to roll out the proof of concept for robotic security solutions. The prototype is in the testing phase now, and we're targeting to launch it in the fourth quarter of 2023."
|
AAL | Hot Stocks07:04 EDT American Airlines reports operating margin of 15.4% for Q2 - The company said, "American produced record quarterly revenues of $14.1 billion in the second quarter. The strong revenue performance was driven by continued broad-based demand strength and American's completion factor performance in the quarter. Demand was particularly strong in the month of June driven by an increase in close-in bookings. Domestic and short-haul international revenue continue to perform well, and the airline has seen noticeable strength in long-haul international demand and yield performance. In the second quarter, the company produced an operating margin of 15.4% and net income of $1.3 billion on a GAAP basis. Excluding net special items, American produced net income of $1.4 billion in the second quarter."
|
GXO HEINY | Hot Stocks07:04 EDT GXO Logistics, HEINEKEN sign multi-year service agreement in the U.K. - GXO Logistics (GXO) announced that it has signed a multi-year agreement with HEINEKEN (HEINY) to continue to operate its warehouse, distribution and secondary transport network to retail and wholesale outlets across the U.K., as well as exclusively to HEINEKEN's entire U.K. pub estate - Star Pubs & Bars. This network manages more than 500,000 deliveries per year to more than 8,000 customers from point of production to retail and wholesale delivery. "We are pleased to continue our partnership with HEINEKEN and look forward to a bright future together," said Richard Cawston, President, Europe, GXO. "Over the past two years, we've made significant progress transforming our operations and delivery network to make it simpler, stronger, more efficient and more sustainable. Together, we will continue to invest to enhance efficiency and service to support HEINEKEN's expected growth. It's a great partnership for us, our team members and the pub industry in the U.K."
|
AAL | Hot Stocks07:03 EDT American Airlines, partners operate nearly 500,000 flights in Q2 - The company said, "The American Airlines team delivered a strong operational performance during the quarter, achieving its best-ever second-quarter completion factor and controllable completion factor. American and its regional partners operated nearly 500,000 flights in the second quarter, with an average load factor of approximately 86%. American delivered a record Memorial Day weekend mainline completion factor and controllable completion factor, while operating its largest-ever mainline Memorial Day weekend schedule. The momentum continued into June, with the American team delivering a record June completion factor and controllable completion factor, despite weather and air traffic control challenges. In the second quarter, American achieved its best-ever April, May and June controllable completion factors and delivered 11 more combined zero-cancellation days versus the same period last year."
|
HLNE | Hot Stocks07:03 EDT Hamilton Lane announces senior leadership changes - Hamilton Lane announced a series of senior leadership changes. Jeffrey Armbrister has been appointed to serve as Hamilton Lane's CFO, succeeding Atul Varma, who is leaving the firm to pursue other interests. Varma will continue in his role as CFO until August 8 and will remain with the firm as a senior advisor over the next several months to facilitate an orderly transition. For the last five years, Armbrister has led the firm's Direct Equity investment business, which earlier this year closed its latest fund on more than $2B of investor commitments. Andrew Schardt will become a Vice Chairman of Hamilton Lane, while retaining his role as Head of Investment Strategy. In both of these capacities Schardt will continue to implement executive-level initiatives while maintaining broader leadership responsibilities across the firm's global investment platform. Schardt will also step into the role of Head of Direct Equity, replacing Armbrister. Effective September 5, Ken Binick will join the firm as Managing Director and Head of Execution on the Direct Equity team, reporting to Schardt. Binick, who most recently served as Co-Head of the Co-Investment business at Portfolio Advisors, brings a distinguished investment track record and extensive operational, team management and transactional experience to the Direct Equity team. Richard Hope, Hamilton Lane's Head of EMEA, will assume the additional role of Co-Head of Investments, alongside Tom Kerr. In this new capacity, Nayef Perry will assume sole leadership of the firm's credit business as Head of Direct Credit, after previously serving as Co-Head alongside Schardt. Since joining Hamilton Lane in 2013, Perry has been instrumental in building the firm's credit platform and capabilities, including management of its 25+ person global Direct Credit team. The changes are effective as of August 8, 2023.
|
TRV | Hot Stocks06:59 EDT Travelers reports Q2 pre-tax catastrophe losses $1.48B vs. $746M last year
|
TRV | Hot Stocks06:58 EDT Travelers says Q2 core income decreased due to higher catastrophe losses
|
ACM | Hot Stocks06:56 EDT Aecom elected by New York City Department of Environmental Protection - AECOM announced it is one of the firms that has been selected by the New York City Department of Environmental Protection, or NYCDEP, to provide design services for the City's cloudburst management program, alleviating nuisance flooding events in at-risk areas. Under this seven-year task-order program, AECOM will implement multi-benefit, integrated, flood risk reduction systems that manage stormwater during wet weather events to improve public spaces, reduce impacts to the natural environment, and bolster the resilience of social, environmental, and economic systems. Cloudburst management involves the design and implementation of multiple, integrated elements to absorb, store and/or transfer stormwater in a specific geographical location or neighborhood.
|
DG | Hot Stocks06:55 EDT Dollar General announces call for diverse suppliers - Dollar General announced a call for diverse suppliers, reflecting its goal to remove or mitigate unintended barriers for diverse suppliers and help increase the representation of these groups in the communities it serves. Applications to apply are currently open online at http://www.rangeme.com/dgdiversity23 through end of day on August 7, 2023, and virtual meetings with Dollar General's supplier diversity team will be held from September 25-29, 2023.
|
ASM | Hot Stocks06:53 EDT Avino Silver & Gold Mines reports Q2 production 587,317 silver equivalent ounces - Silver equivalent production decreased 10% to 587,317 ounces. Silver production increased 3% to 232,417 ounces. Copper production decreased 12% to 1.45M pounds. Gold production increased 13% to 1,520 ounces. Mill throughput increased by 33% to 157,371 tons. "The Avino Mine continued to provide stable production results in the second quarter of 2023, albeit impacted by mining in lower grade areas and certain mill equipment delivery delays, which are now behind us," said David Wolfin, president and CEO of Avino. "These challenges provided us with the opportunity to implement upgrades to the haulage ramp that has since allowed us to exceed original underground maximum haulage rates. With these upgrades, we expect production to catch up to our internal guidance in the second half of the year. On the exploration side, we are thrilled with the outstanding drill results from below Level 17 released earlier this month which further demonstrates that the Avino Mine continues to get better as we explore at depth. Finally, we remain focused on the execution of our 5-year growth plan."
|
DRUG | Hot Stocks06:51 EDT Bright Minds Biosciences completes three-part Phase 1 study of BMB-101 - Bright Minds Biosciences announced the successful completion of its three-part Phase 1 study of BMB-101. The study, conducted in Adelaide, Australia, by CMAX Clinical Research, a clinical trial center specializing in a range of early-phase trials and first-in-human studies, evaluated the safety, tolerability, pharmacokinetic, and food effect in healthy volunteers. MB-101 is a highly selective and potent 5-HT2C agonist being developed for the treatment of refractory epilepsies and other indications, such as psychosis, addiction, and impulse control disorders. BMB-101 demonstrated an excellent safety and tolerability profile. 5-HT2C target engagement was demonstrated by transient, dose-dependent increases in prolactin. BMB-101 exhibited predictable plasma pharmacokinetics with relatively small inter-individual variability. The Company is currently awaiting the qEEG, or Quantitative Electroencephalogram, data and will provide a more detailed discussion of the Phase 1 results when available.
|
EXK | Hot Stocks06:51 EDT Endeavour Silver provides Q2 construction update on the Terronera Project - Endeavour Silver is pleased to provide a construction update for its Terronera Project in Jalisco state, Mexico. "The seasoned construction team that we have assembled has been meeting the challenges and we continue making good progress," commented Don Gray, COO. "Our advanced planning is now paying off with timely equipment deliveries and disciplined field execution that's keeping the project on schedule and within budget. We expect to award the mill construction contract in Q4, which will kick off the next major construction phase. Meeting key project milestones is important to both Terronera' s success and to achieving Endeavour's industry-leading, silver dominant transformational growth."
|
ELYM | Hot Stocks06:46 EDT Eliem Therapeutics plans to explore strategic alternatives - Eliem Therapeutics announced that it has completed a review of its business, including the status of its programs, resources, and capabilities, and has made the determination to halt further development of its Kv7 program and to conduct a comprehensive exploration of strategic alternatives focused on maximizing shareholder value. Eliem has engaged Leerink Partners to act as a strategic advisor in the process. As part of this process, Eliem will explore potential strategic alternatives that may include, but are not limited to, an acquisition, merger, business combination, or other transaction. As of June 30, the Company had a preliminary unaudited amount of approximately $102.6M in cash, cash equivalents and investments in marketable securities.
|
IIIN | Hot Stocks06:41 EDT Insteel sees 'modest recovery to continue' in Q4 - "Given the lethargic market conditions we experienced during the third quarter, our financial performance was reasonable, reflecting the easing of headwinds that negatively impacted our results for the first half of fiscal 2023. Shipments and spreads improved during the quarter as inventory levels moderated, although shipment volume was well below our expectations," commented H.O. Woltz III, Insteel's President and CEO. "As we head into the fourth fiscal quarter, we expect the modest recovery to continue driven by nonresidential construction activity and the recovery in residential markets." Woltz continued, "The outlook for infrastructure construction remains favorable as federal spending from the Infrastructure Investment and Jobs Act is expected to begin to drive demand as we move into the second half of the calendar year and beyond. Additionally, we continued to progress towards completing several ongoing capital projects focused on broadening our product offering, expanding our capacity, and reducing operating costs. We expect the first two projects to be fully commissioned in our fourth fiscal quarter, followed by the remaining project in the first quarter of fiscal 2024."
|
AULT | Hot Stocks06:40 EDT Ault subsidiary Gresham exceeded $10.2M in bookings in Q2 - Ault Alliance announced its majority owned subsidiary, Giga-tronics, d/b/a Gresham Worldwide, a provider of high-performance purpose-built electronic solutions for mission critical applications in defense, health care, telecommunications, and transportation industries, exceeded $10.2M in bookings for the quarter ending June 30. Gresham Worldwide booked orders for turnkey electronic solutions, particularly for defense and health care customers, as well as radio frequency component solutions, power electronics and displays. The new orders included orders for missile defense technology and RF solutions for global defense contractors as well medical device test solutions for a Fortune 50 global healthcare provider. Continued geopolitical military tensions and post-pandemic business rebounds drove increased demand for Gresham Worldwide's offerings in the Q2. Those factors are expected by Gresham Worldwide to generate increasing demand for precision electronics throughout the rest of 2023 and into 2024. Gresham Worldwide ended the Q2 with an order backlog of $28M, which Gresham Worldwide believes will pave the way for continued, stable growth.
|
EGAN | Hot Stocks06:38 EDT eGain announces partnership with Talkdesk - eGain announced a partnership with Talkdesk, a global cloud contact center leader for enterprises of all sizes, to help businesses modernize customer service with the AI-infused knowledge management and rich digital capabilities. The partnership brings to market a new offering, the Talkdesk-eGain Connector, which is listed on both companies' marketplaces - Talkdesk AppConnect and eGain Marketplace. The connector includes two integrations that embed eGain's knowledge and digital capabilities in the Talkdesk Agent Workspace.
|
MKTX | Hot Stocks06:37 EDT MarketAxess reconfirms previously stated full-year 2023 guidance - The company is reconfirming its previously stated full-year 2023 guidance for operating expenses, effective tax rate and capital expenditures.
|
DHI | Hot Stocks06:35 EDT D.R. Horton reports Q3 homebuilding revenue of $8.7B - Net sales orders for the third quarter ended June 30, 2023 increased 37% to 22,879 homes and 26% in value to $8.7 billion compared to 16,693 homes and $6.9 billion in the same quarter of the prior year. The Company's cancellation rate for the third quarter of fiscal 2023 was 18% compared to 24% in the prior year quarter. Net sales orders for the first nine months of fiscal 2023 decreased 5% to 59,403 homes and 11% in value to $22.3 billion compared to 62,555 homes and $24.9 billion in the same period of fiscal 2022. The Company's sales order backlog of homes under contract at June 30, 2023 decreased 34% to 19,186 homes and 38% in value to $7.4 billion compared to 29,244 homes and $11.9 billion at June 30, 2022. At June 30, 2023, the Company had 43,800 homes in inventory, of which 25,000 were unsold. 5,700 of the Company's unsold homes at June 30, 2023 were completed. The Company's homebuilding land and lot portfolio totaled 555,100 lots at the end of the quarter, of which 25% were owned and 75% were controlled through land and lot purchase contracts.
|
NNDM | Hot Stocks06:35 EDT Nano Dimension continues to purse claims against Murchinson, Anson, and Boothbay - Nano Dimension announced that it is continuing to pursue claims against Murchinson, Anson, and Boothbay in New York. On July 14th, 2023, Nano filed a complaint against Defendants Murchinson Ltd., Anson Advisors, Inc., Boothbay Fund Management, LLC and their affiliates in the Supreme Court of the State of New York. The Complaint seeks to redress Defendants' alleged misconduct, including their improper scheme to secretly acquire an interest in Nano and attempt to take control of the company and dissipate its assets, in breach of the contract that governs the Nano American Depositary Shares Defendants hold and in violation of New York law.
|
SNA | Hot Stocks06:31 EDT Snap-On sees 2023 CapEx about $100M - "We believe that our markets and our operations possess and have demonstrated continuing and considerable resilience against the uncertainties of the current environment. In 2023, Snap-on expects to make ongoing progress along its defined runways for coherent growth, leveraging capabilities already demonstrated in the automotive repair arena and developing and expanding its professional customer base, not only in automotive repair, but in adjacent markets, additional geographies and other areas, including extending in critical industries, where the cost and penalties for failure can be high. In pursuit of these initiatives, we project that capital expenditures in 2023 will approximate $100 million, of which $48.8 million was incurred in the first six months of the year. Snap-on currently anticipates that its full year 2023 effective income tax rate will be in the range of 23% to 24%."
|
GMAB JNJ | Hot Stocks06:27 EDT Genmab reports Q2 worldwide net sales of DARZALEX $2.43B - Genmab (GMAB) announced that worldwide net trade sales of DARZALEX, including sales of the subcutaneous product, as reported by Johnson & Johnson (JNJ) were $2.431B in the second quarter of 2023. Net trade sales were $1.322B in the U.S. and $1.11B in the rest of the world. Genmab receives royalties on the worldwide net sales of DARZALEX, both the intravenous and SC products, under the exclusive worldwide license to Janssen to develop, manufacture and commercialize daratumumab.
|
PSN | Hot Stocks06:27 EDT Parsons selected by Naval Facility Engineering Systems Command Southwest - Parsons announced that the company was selected by Naval Facility Engineering Systems Command Southwest, or NAVFAC SW, to provide project performance assessment, or PPA, and programmatic risk management, or PRM, services for the Facility Engineering Command's construction program. The $11M contract consists of a one-year base period of performance with three one-year option periods and is new work for the company. NAVFAC SW is one of seven Facilities Engineering Commands within NAVFAC Pacific and advances the U.S. Indo-Asia-Pacific Maritime Strategy through planning, building, and maintaining sustainable facilities and delivering environmental, utilities, and other base services. Under this contract, Parsons will provide PPA and PRM to the federal government for the development and execution phases of construction projects for the NAVFAC SW construction program, which totals approximately $1.3B in annual work at Travis Air Force Base and Navy and Marine Corps installations throughout the southwest U.S.
|
JNJ | Hot Stocks06:24 EDT Johnson & Johnson intends to 'split off' Kenvue shares through an exchange offer - Johnson & Johnson intends to "split off" Kenvue shares through an exchange offer as the form of its next step in the separation, subject to market conditions.
|
KVUE | Hot Stocks06:24 EDT Kenvue initiates quarterly dividend of 20c per share - Kenvue announced that its Board of Directors has declared a dividend payable in the third quarter of 2023 of 20c per share on the company's common stock. The third quarter dividend is payable on September 7 to shareholders of record as of the close of business on August 28.
|
NVS | Hot Stocks06:07 EDT Novartis' Sandoz to build Biosimilar Technical Development Center in Slovenia - Sandoz, a Novartis division, announced an investment of approximately $90M at its site in Ljubljana, Slovenia to establish a dedicated Sandoz Biopharma Development Center by 2026. "With this investment, the Ljubljana site will become one of the key locations for biosimilar product development at Sandoz. The new site will lead to the creation of approximately 200 new full-time jobs and further strengthen the company's capabilities in end-to-end drug substance and drug product development of biosimilars. The planned investment complements recently announced Sandoz plans to invest at least USD 400 million in a new biologics manufacturing plant in Lendava, Slovenia, as well as expanding its biosimilar development capabilities at its facility in Holzkirchen, Germany. It also builds on existing small molecule product development capabilities in Ljubljana, where Sandoz has successfully established comprehensive capabilities to develop technologically complex generic pharmaceuticals," the company stated.
|
KBR | Hot Stocks06:07 EDT KBR awarded $69M CENTCOM contract - KBR announced it has been awarded a contract to provide mission-critical labor at three locations in the U.S. Central Command, or CENTCOM, area of operations. The cost-plus contract, through the Air Force Contract Augmentation Program, or AFCAP V, is worth up to $69M and has a base period of two years with an eight-month option. Under the terms of the contract, KBR will provide support personnel at Ali Al Salem Air Base, Kuwait; Prince Sultan Air Base, Saudi Arabia; and Al Dhafra Air Base, UAE, over the next two and a half years. KBR personnel will accompany and guide local and other country nationals at U.S. military facilities throughout these three bases. This contract in the CENTCOM area of operations expands KBR's portfolio in the region, where the company already performs base operations support in Bahrain, United Arab Emirates, and Saudi Arabia.
|
ATAT | Hot Stocks06:05 EDT Atour Lifestyle names Jianfeng Wu as co-CFO - Atour Lifestyle announced the appointment of Jianfeng Wu as Co-CFO of the company, effective July 20. Wu will be primarily responsible for overseeing the company's capital market matters, including investor relations and financing management, as well as providing administrative and other support to the Board and assisting in daily operations. Prior to joining Atour, Wu spent eight years with CMB International Capital Limited, where he has served as a Managing Director, a member of Investment Banking Business Management Committee and the Head of Consumer sector in the Corporate Finance Department
|
EL MANU | Hot Stocks06:03 EDT Estee Lauder, Manchester United announce partnership - Estee Lauder (EL) will team up with renowned football club, Manchester United (MANU), to reach and engage their extensive fanbase in China and the Asia Pacific region, a first-of-its-kind partnership for the brand. Estee Lauder continues its legacy of disrupting the beauty industry, bringing its high-performing products to new communities of sports fans who demand peak performance in every aspect of life. Kicking off in Summer 2023, the partnership's inaugural campaign will launch with players from Manchester United's first team, including Marcus Rashford, Luke Shaw, Alejandro Garnacho and Raphael Varane. Bringing together the worlds of beauty and sports, the campaign will engage fans across Manchester United's social platforms - with a reach of more than 250M in China alone - with dynamic social storytelling around the benefits of recharging the skin. The partnership will initially spotlight Estee Lauder Advanced Night Repair Serum, an industry disruptor, and one of the best-selling, most-loved skincare products in the brand's history. The master multi-tasking Advanced Night Repair performs like 7 serums in 1, featuring an exclusive ingredient, Tripeptide-32, to help optimize skin's own rhythm of daytime protection and night-time repair. Just one dropper morning and evening reveals energized, refreshed, and hydrated skin.
|
ALLT | Hot Stocks05:31 EDT Allot Ltd. announces DNS Secure selected by Tier-1 telecom operator - Allot Ltd. announced that a Tier-1 telecom operator, with more than 50M mostly prepaid customers in Asia, has selected Allot DNS Secure to offer cybersecurity threat protection and comprehensive parental control services to its mobile customers. These services will initially be offered to postpaid customers and then potentially to other high value customers, as well. Allot is entitled to a recurring monthly fee based on the number of actual users.
|
NNDM SSYS | Hot Stocks05:29 EDT Nano Dimension expands on intentions on regarding Stratasys board changes - Nano Dimension (NNDM), which owns approximately 14.1% of Stratasys' (SSYS), expanded on its intentions regarding the composition of the Stratasys board of directors. The company said, "Nano Dimension, by necessity, is acting with urgency to initiate the replacement of Stratasys' directors in the interest of all shareholders. As a result, Nano nominated seven highly qualified directors with extensive track records of value creation. As Nano has detailed previously, all of its nominees have previously served as CEOs or in "C-suite" positions, through which they have created demonstrable increases in long-term shareholder value. Almost all of Nano's candidates have multiple decades of global business experience in technology, finance, M&A and operations in manufacturing and related sectors. While Nano had asked the court to allow Stratasys shareholders to pick and choose across nominees from both companies, Stratasys has chosen to take that option away from its shareholders, forcing its shareholders to select a full slate. Nano fully recognizes that the Board should be comprised of a majority of independent directors and, following a successful replacement of the current Stratasys' directors with Nano's director nominees, intends to take steps to appoint independent directors to represent Stratasys shareholders' interests for the long term, at which time Nano Dimension's nominees would cycle off the Board such that a majority of the Board would be independent over time. Nano Dimension's director nominees are intended as an interim but urgently needed solution to prevent further value destruction by the current Stratasys Board. Nano Dimension urges Stratasys shareholders to vote "FOR" the nominees proposed by Nano Dimension at Stratasys' Annual General Meeting to be held on August 8th, 2023, in order to replace the majority of the current Stratasys Board."
|
NKLA | Hot Stocks05:27 EDT Nikola to sell Phoenix Hydrogen Hub to Fortescue Future Industries - Nikola and Fortescue Future Industries, or FFI, announced FFI will acquire Nikola's Phoenix Hydrogen Hub, or PHH, project. FFI will bring the capital and resources required to fully develop the project and the parties are working towards a hydrogen supply agreement to support Nikola's Class 8 zero-emission trucks. The PHH is a fast-to-market, green hydrogen project located near Phoenix, in the city of Buckeye, Arizona, and is expected to be built in phases to scale alongside demand. The project is expected to progress towards its first hydrogen production by the middle of this decade. PHH marks the first project announced as part of the memorandum of understanding signed in January between the two companies to collaborate on and evaluate the co-development of large-scale U.S. green hydrogen production facilities. FFI and Nikola are working towards a hydrogen supply agreement to support Nikola's hydrogen fuel cell electric vehicle demand. The large-scale deployment of hydrogen as a zero-emission fuel into the transportation sector, is expected to benefit from both the hydrogen tax credit in the federal Inflation Reduction Act and state level incentives such as the Low Carbon Fuel Standard in California. The PHH project is currently going through the final stages of its permitting process, and the procurement of long-lead equipment is well underway.
|
J | Hot Stocks05:11 EDT Jacobs selected by USNC to support new nuclear reactor - Jacobs was selected by Ultra Safe Nuclear Corporation U.K., or USNC, to support design and development of a new micro modular power reactor, or MMR. The U.K. Department for Energy Security and Net Zero has awarded USNC a grant of up to $29 million toward the development cost of the MMR Energy System, which is designed to support the transition away from fossil fuels. The grant, match funded by USNC, will enable the second phase of work toward building a U.K. demonstrator of the high-temperature gas-cooled reactor by the early 2030s.
|